Podcasts about Cerner

Join us for this episode with Dr. Craig Joseph, Chief Medical Officer at Nordic Global and co-author of Designing for Health. Craig shares his journey from practicing pediatrics to becoming a national thought leader in healthcare IT and clinical informatics. We dive into his experience with EHRs like Epic and Cerner, the challenges of designing tech doctors actually want to use, and where AI fits into the future of patient care.This is a great episode if you're exploring careers at the intersection of medicine and technology or curious about human-centered design in healthcare. If you enjoy the show, be sure to share it with a friend and leave a comment!

This episode's Community Champion Sponsor is Ossur. To learn more about their ‘Responsible for Tomorrow' Sustainability Campaign, and how you can get involved: CLICK HEREEpisode Overview: Healthcare's integration challenges have reached a critical juncture where clinicians demand seamless technology that enhances rather than hinders patient care. Our next guest, John Orosco, is revolutionizing this landscape as CEO of Red Rover Health. With over 25 years of healthcare IT experience, including his foundational role at Cerner developing their first API platform, John witnessed firsthand how rigid integration systems stifle innovation. This insight led him to co-found Red Rover Health, creating a normalized SaaS platform that serves as "the App Store for healthcare." By enabling true best-of-breed solutions through standardized APIs, John is breaking down the barriers that have long frustrated healthcare organizations. Join us to discover how Red Rover's pioneering approach is empowering providers to choose the tools they need while maintaining seamless EHR connectivity. Let's go!Episode Highlights:Healthcare's open integration platforms often get shut down when they threaten vendor sales of proprietary solutionsRed Rover Health serves as "the App Store for healthcare," enabling seamless third-party app integration with EHR systemsThe joke "if you've seen one HL7 interface, you've seen one" reflects how every integration requires custom codeHealthcare CIOs often function as "EMR administrators" rather than true technology innovatorsAI/ML represents the next frontier, with Red Rover positioning to enhance data access with AI-powered insightsAbout our Guest: John is a healthcare IT entrepreneur and expert in Electronic Health Record (EHR) integration with over 25 years of experience. He started as a software developer at Cerner Corporation, where he led the first Millennium RESTful integration team. John later founded JASE Health, providing custom EHR integrations for healthcare IT vendors, before co-founding Red Rover Health to develop a normalized SaaS platform for EHR integration. John is dedicated to solving complex EHR challenges and enabling healthcare providers to implement best-of-breed solutions regardless of their EHR system.Links Supporting This Episode: RedRover Health Website: CLICK HEREJohn Orosco LinkedIn page: CLICK HERERed Rover Health LinkedIn: CLICK HEREMike Biselli LinkedIn page: CLICK HEREMike Biselli Twitter page: CLICK HEREVisit our website: CLICK HERESubscribe to newsletter: CLICK HEREGuest nomination form: CLICK HERE

In this episode, Lois Houston and Nikita Abraham continue their deep dive into Oracle GoldenGate 23ai, focusing on its evolution and the extensive features it offers. They are joined once again by Nick Wagner, who provides valuable insights into the product's journey.   Nick talks about the various iterations of Oracle GoldenGate, highlighting the significant advancements from version 12c to the latest 23ai release. The discussion then shifts to the extensive new features in 23ai, including AI-related capabilities, UI enhancements, and database function integration.   Oracle GoldenGate 23ai: Fundamentals: https://mylearn.oracle.com/ou/course/oracle-goldengate-23ai-fundamentals/145884/237273 Oracle University Learning Community: https://education.oracle.com/ou-community LinkedIn: https://www.linkedin.com/showcase/oracle-university/ X: https://x.com/Oracle_Edu   Special thanks to Arijit Ghosh, David Wright, Kris-Ann Nansen, Radhika Banka, and the OU Studio Team for helping us create this episode.   -----------------------------------------------------------------   Episode Transcript: 00:00 Welcome to the Oracle University Podcast, the first stop on your cloud journey. During this series of informative podcasts, we'll bring you foundational training on the most popular Oracle technologies. Let's get started! 00:25 Lois: Hello and welcome to the Oracle University Podcast! I'm Lois Houston, Director of Innovation Programs with Oracle University, and with me is Nikita Abraham, Team Lead: Editorial Services.  Nikita: Hi everyone! Last week, we introduced Oracle GoldenGate and its capabilities, and also spoke about GoldenGate 23ai. In today's episode, we'll talk about the various iterations of Oracle GoldenGate since its inception. And we'll also take a look at some new features and the Oracle GoldenGate product family. 00:57 Lois: And we have Nick Wagner back with us. Nick is a Senior Director of Product Management for GoldenGate at Oracle. Hi Nick! I think the last time we had an Oracle University course was when Oracle GoldenGate 12c was out. I'm sure there's been a lot of advancements since then. Can you walk us through those? Nick: GoldenGate 12.3 introduced the microservices architecture. GoldenGate 18c introduced support for Oracle Autonomous Data Warehouse and Autonomous Transaction Processing Databases. In GoldenGate 19c, we added the ability to do cross endian remote capture for Oracle, making it easier to set up the GoldenGate OCI service to capture from environments like Solaris, Spark, and HP-UX and replicate into the Cloud. Also, GoldenGate 19c introduced a simpler process for upgrades and installation of GoldenGate where we released something called a unified build. This means that when you install GoldenGate for a particular database, you don't need to worry about the database version when you install GoldenGate. Prior to this, you would have to install a version-specific and database-specific version of GoldenGate. So this really simplified that whole process. In GoldenGate 23ai, which is where we are now, this really is a huge release.  02:16 Nikita: Yeah, we covered some of the distributed AI features and high availability environments in our last episode. But can you give us an overview of everything that's in the 23ai release? I know there's a lot to get into but maybe you could highlight just the major ones? Nick: Within the AI and streaming environments, we've got interoperability for database vector types, heterogeneous capture and apply as well. Again, this is not just replication between Oracle-to-Oracle vector or Postgres to Postgres vector, it is heterogeneous just like the rest of GoldenGate. The entire UI has been redesigned and optimized for high speed. And so we have a lot of customers that have dozens and dozens of extracts and replicats and processes running and it was taking a long time for the UI to refresh those and to show what's going on within those systems. So the UI has been optimized to be able to handle those environments much better. We now have the ability to call database functions directly from call map. And so when you do transformation with GoldenGate, we have about 50 or 60 built-in transformation routines for string conversion, arithmetic operation, date manipulation. But we never had the ability to directly call a database function. 03:28 Lois: And now we do? Nick: So now you can actually call that database function, database stored procedure, database package, return a value and that can be used for transformation within GoldenGate. We have integration with identity providers, being able to use token-based authentication and integrate in with things like Azure Active Directory and your other single sign-on for the GoldenGate product itself. Within Oracle 23ai, there's a number of new features. One of those cool features is something called lock-free reservation columns. So this allows you to have a row, a single row within a table and you can identify a column within that row that's like an inventory column. And you can have multiple different users and multiple different transactions all updating that column within that same exact row at that same time. So you no longer have row-level locking for these reservation columns. And it allows you to do things like shopping carts very easily. If I have 500 widgets to sell, I'm going to let any number of transactions come in and subtract from that inventory column. And then once it gets below a certain point, then I'll start enforcing that row-level locking. 04:43 Lois: That's really cool… Nick: The one key thing that I wanted to mention here is that because of the way that the lock-free reservations work, you can have multiple transactions open on the same row. This is only supported for Oracle to Oracle. You need to have that same lock-free reservation data type and availability on that target system if GoldenGate is going to replicate into it. 05:05 Nikita: Are there any new features related to the diagnosability and observability of GoldenGate?  Nick: We've improved the AWR reports in Oracle 23ai. There's now seven sections that are specific to Oracle GoldenGate to allow you to really go in and see exactly what the GoldenGate processes are doing and how they're behaving inside the database itself. And there's a Replication Performance Advisor package inside that database, and that's been integrated into the Web UI as well. So now you can actually get information out of the replication advisor package in Oracle directly from the UI without having to log into the database and try to run any database procedures to get it. We've also added the ability to support a per-PDB Extract.  So in the past, when GoldenGate would run on a multitenant database, a multitenant database in Oracle, all the redo data from any pluggable database gets sent to that one redo stream. And so you would have to configure GoldenGate at the container or root level and it would be able to access anything at any PDB. Now, there's better security and better performance by doing what we call per-PDB Extract. And this means that for a single pluggable database, I can have an extract that runs at that database level that's going to capture information just from that pluggable database. 06:22 Lois And what about non-Oracle environments, Nick? Nick: We've also enhanced the non-Oracle environments as well. For example, in Postgres, we've added support for precise instantiation using Postgres snapshots. This eliminates the need to handle collisions when you're doing Postgres to Postgres replication and initial instantiation. On the GoldenGate for big data side, we've renamed that product more aptly to distributed applications in analytics, which is really what it does, and we've added a whole bunch of new features here too. The ability to move data into Databricks, doing Google Pub/Sub delivery. We now have support for XAG within the GoldenGate for distributed applications and analytics. What that means is that now you can follow all of our MAA best practices for GoldenGate for Oracle, but it also works for the DAA product as well, meaning that if it's running on one node of a cluster and that node fails, it'll restart itself on another node in the cluster. We've also added the ability to deliver data to Redis, Google BigQuery, stage and merge functionality for better performance into the BigQuery product. And then we've added a completely new feature, and this is something called streaming data and apps and we're calling it AsyncAPI and CloudEvent data streaming. It's a long name, but what that means is that we now have the ability to publish changes from a GoldenGate trail file out to end users. And so this allows through the Web UI or through the REST API, you can now come into GoldenGate and through the distributed applications and analytics product, actually set up a subscription to a GoldenGate trail file. And so this allows us to push data into messaging environments, or you can simply subscribe to changes and it doesn't have to be the whole trail file, it can just be a subset. You can specify exactly which tables and you can put filters on that. You can also set up your topologies as well. So, it's a really cool feature that we've added here. 08:26 Nikita: Ok, you've given us a lot of updates about what GoldenGate can support. But can we also get some specifics? Nick: So as far as what we have, on the Oracle Database side, there's a ton of different Oracle databases we support, including the Autonomous Databases and all the different flavors of them, your Oracle Database Appliance, your Base Database Service within OCI, your of course, Standard and Enterprise Edition, as well as all the different flavors of Exadata, are all supported with GoldenGate. This is all for capture and delivery. And this is all versions as well. GoldenGate supports Oracle 23ai and below. We also have a ton of non-Oracle databases in different Cloud stores. On an non-Oracle side, we support everything from application-specific databases like FairCom DB, all the way to more advanced applications like Snowflake, which there's a vast user base for that. We also support a lot of different cloud stores and these again, are non-Oracle, nonrelational systems, or they can be relational databases. We also support a lot of big data platforms and this is part of the distributed applications and analytics side of things where you have the ability to replicate to different Apache environments, different Cloudera environments. We also support a number of open-source systems, including things like Apache Cassandra, MySQL Community Edition, a lot of different Postgres open source databases along with MariaDB. And then we have a bunch of streaming event products, NoSQL data stores, and even Oracle applications that we support. So there's absolutely a ton of different environments that GoldenGate supports. There are additional Oracle databases that we support and this includes the Oracle Metadata Service, as well as Oracle MySQL, including MySQL HeatWave. Oracle also has Oracle NoSQL Spatial and Graph and times 10 products, which again are all supported by GoldenGate. 10:23 Lois: Wow, that's a lot of information! Nick: One of the things that we didn't really cover was the different SaaS applications, which we've got like Cerner, Fusion Cloud, Hospitality, Retail, MICROS, Oracle Transportation, JD Edwards, Siebel, and on and on and on.  And again, because of the nature of GoldenGate, it's heterogeneous. Any source can talk to any target. And so it doesn't have to be, oh, I'm pulling from Oracle Fusion Cloud, that means I have to go to an Oracle Database on the target, not necessarily.  10:51 Lois: So, there's really a massive amount of flexibility built into the system.  11:00 Unlock the power of AI Vector Search with our new course and certification. Get more accurate search results, handle complex datasets easily, and supercharge your data-driven decisions. From now through May 15, 2025, we are waiving the certification exam fee (valued at $245). Visit mylearn.oracle.com to enroll. 11:26 Nikita: Welcome back! Now that we've gone through the base product, what other features or products are in the GoldenGate family itself, Nick? Nick: So we have quite a few. We've kind of touched already on GoldenGate for Oracle databases and non-Oracle databases. We also have something called GoldenGate for Mainframe, which right now is covered under the GoldenGate for non-Oracle, but there is a licensing difference there. So that's something to be aware of. We also have the OCI GoldenGate product. We are announcing and we have announced that OCI GoldenGate will also be made available as part of the Oracle Database@Azure and Oracle Database@ Google Cloud partnerships.  And then you'll be able to use that vendor's cloud credits to actually pay for the OCI GoldenGate product. One of the cool things about this is it will have full feature parity with OCI GoldenGate running in OCI. So all the same features, all the same sources and targets, all the same topologies be able to migrate data in and out of those clouds at will, just like you do with OCI GoldenGate today running in OCI.  We have Oracle GoldenGate Free.  This is a completely free edition of GoldenGate to use. It is limited on the number of platforms that it supports as far as sources and targets and the size of the database.  12:45 Lois: But it's a great way for developers to really experience GoldenGate without worrying about a license, right? What's next, Nick? Nick: We have GoldenGate for Distributed Applications and Analytics, which was formerly called GoldenGate for big data, and that allows us to do all the streaming. That's also where the GoldenGate AsyncAPI integration is done. So in order to publish the GoldenGate trail files or allow people to subscribe to them, it would be covered under the Oracle GoldenGate Distributed Applications and Analytics license. We also have OCI GoldenGate Marketplace, which allows you to run essentially the on-premises version of GoldenGate but within OCI. So a little bit more flexibility there. It also has a hub architecture. So if you need that 99.99% availability, you can get it within the OCI Marketplace environment. We have GoldenGate for Oracle Enterprise Manager Cloud Control, which used to be called Oracle Enterprise Manager. And this allows you to use Enterprise Manager Cloud Control to get all the statistics and details about GoldenGate. So all the reporting information, all the analytics, all the statistics, how fast GoldenGate is replicating, what's the lag, what's the performance of each of the processes, how much data am I sending across a network. All that's available within the plug-in. We also have Oracle GoldenGate Veridata. This is a nice utility and tool that allows you to compare two databases, whether or not GoldenGate is running between them and actually tell you, hey, these two systems are out of sync. And if they are out of sync, it actually allows you to repair the data too. 14:25 Nikita: That's really valuable…. Nick: And it does this comparison without locking the source or the target tables. The other really cool thing about Veridata is it does this while there's data in flight. So let's say that the GoldenGate lag is 15 or 20 seconds and I want to compare this table that has 10 million rows in it. The Veridata product will go out, run its comparison once. Once that comparison is done the first time, it's then going to have a list of rows that are potentially out of sync. Well, some of those rows could have been moved over or could have been modified during that 10 to 15 second window. And so the next time you run Veridata, it's actually going to go through. It's going to check just those rows that were potentially out of sync to see if they're really out of sync or not. And if it comes back and says, hey, out of those potential rows, there's two out of sync, it'll actually produce a script that allows you to resynchronize those systems and repair them. So it's a very cool product.  15:19 Nikita: What about GoldenGate Stream Analytics? I know you mentioned it in the last episode, but in the context of this discussion, can you tell us a little more about it?  Nick: This is the ability to essentially stream data from a GoldenGate trail file, and they do a real time analytics on it. And also things like geofencing or real-time series analysis of it.  15:40 Lois: Could you give us an example of this? Nick: If I'm working in tracking stock market information and stocks, it's not really that important on how much or how far down a stock goes. What's really important is how quickly did that stock rise or how quickly did that stock fall. And that's something that GoldenGate Stream Analytics product can do. Another thing that it's very valuable for is the geofencing. I can have an application on my phone and I can track where the user is based on that application and all that information goes into a database. I can then use the geofencing tool to say that, hey, if one of those users on that app gets within a certain distance of one of my brick-and-mortar stores, I can actually send them a push notification to say, hey, come on in and you can order your favorite drink just by clicking Yes, and we'll have it ready for you. And so there's a lot of things that you can do there to help upsell your customers and to get more revenue just through GoldenGate itself. And then we also have a GoldenGate Migration Utility, which allows customers to migrate from the classic architecture into the microservices architecture. 16:44 Nikita: Thanks Nick for that comprehensive overview.  Lois: In our next episode, we'll have Nick back with us to talk about commonly used terminology and the GoldenGate architecture. And if you want to learn more about what we discussed today, visit mylearn.oracle.com and take a look at the Oracle GoldenGate 23ai Fundamentals course. Until next time, this is Lois Houston… Nikita: And Nikita Abraham, signing off! 17:10 That's all for this episode of the Oracle University Podcast. If you enjoyed listening, please click Subscribe to get all the latest episodes. We'd also love it if you would take a moment to rate and review us on your podcast app. See you again on the next episode of the Oracle University Podcast.

How is AI used in health care data? What does AI help with in health care? How is AI used in emergency rooms? What are the benefits of AI in health care? How is AI used in medical documentation? Learn about using AI in electronic health records to improve patient care and the future of AI in health care with guest Dana Sax, MD, research scientist at Kaiser Permanente Division of Research and emergency physician at The Permanente Medical Group. American Medical Association CXO Todd Unger hosts.

In early 2025, Oracle faced two significant cybersecurity breaches that exposed sensitive data and raised serious concerns about its security practices. The first breach involved outdated Cerner servers, compromising healthcare data, while the second targeted an inactive legacy system, leading to the theft of client credentials. Both incidents highlighted critical vulnerabilities in Oracle's infrastructure and the importance of timely detection and response. The aftermath included a class action lawsuit and ongoing investigations, emphasizing the need for robust cybersecurity measures and transparency in handling breaches. Catch the Video: https://youtu.be/YWAmzPmG0YMTakeaways•    Oracle was breached twice in early 2025, raising alarms.•    The first breach compromised healthcare data via outdated servers.•    The second breach involved an inactive legacy system.•    Hackers exploited known vulnerabilities to gain access.•    Delayed detection allowed unauthorized access for weeks.•    Oracle's response included denying the breaches initially.•    A class action lawsuit was filed against Oracle for negligence.•    Legacy systems pose significant security risks if not decommissioned.•    Timely detection and monitoring are crucial for cybersecurity.•    Organizations must prioritize patch management and system updates.Send us a textGrowth without Interruption. Get peace of mind. Stay Competitive-Get NetGain. Contact NetGain today at 844-777-6278 or reach out online at www.NETGAINIT.com

The goal of this mini series is to spark conversations of these new tools and practices within the community of current and future medical practitioners and staff. It is important for medical professionals to have a say in how these AI tools impact practice to ensure practical and ethical use. Join us in discussions of the history of AI, machine and deep learning, computer visions, natural language processing, responsible AI, and so much more. Let's take a step into the future together.To kick off our first episode of this series we have Dr. Mehul Sheth, the medical director for health informatics for Illinois and Indiana based at Loyola. For his training, Dr. Sheth went to Midwestern University for medical school after which he completed a residency in pediatrics at University of Illinois Chicago. Dr. Sheth has been working in clinical informatics full-time for over 12 years most recently with oracle (formerly Cerner) where he was a member of the AI board and supported the development of machine learning algorithms and generative AI tools like Sax and Actions assist. In this episode we discuss various topics in AI and medicine including its history, capabilities and limitations, current applications, how to prepare for AI's impact in medicine, and a special announcement of a new AI elective at Stritch!Episode produced by: Rohan SethiEpisode recording date: 02/04/2025www.medicuspodcast.com | medicuspodcast@gmail.com | Donate: http://bit.ly/MedicusDonate

L'invité : Arnaud Orain, économiste et historien, directeur d'études à l'EHESS Le livre : Le monde confisqué, essai sur le capitalisme de la finitude, XVIe-XXIe siècles, Paris, Flammarion, 2025. La discussion : Cerner le « capitalisme de la finitude » (1:00) Est-on sorti du néolibéralisme ? (6:35) Une lecture cyclique de l'histoire du capitalisme (11:00) La naissance du capitalisme de la … Continue reading "375. Retour au capitalisme illibéral, avec Arnaud Orain"

Drex covers two separate Oracle security incidents affecting healthcare organizations. The Rose87168 hacking group claims to have stolen 6 million user records from Oracle Cloud, now for sale on the dark web. Oracle denies the breach, but independent researchers confirm data authenticity. A second breach on older Cerner servers (not yet migrated to Oracle Cloud) exposed patient medical information, with hackers attempting to extort several US healthcare organizations. The full scope of affected organizations and patients remains unknown but healthcare customers report dissatisfaction with Oracle's lack of transparency and response to these incidents.Remember, Stay a Little Paranoid X: This Week Health LinkedIn: This Week Health Donate: Alex's Lemonade Stand: Foundation for Childhood Cancer

In this episode of Thriving Practice, we welcome back Kyle Kiser, co-founder of ArriveHealth, to discuss the company's remarkable growth and its innovative solutions in healthcare technology. Since our last conversation a little over a year ago, ArriveHealth has doubled its revenue, a testament to the value of their real-time benefit network. Kyle shares how their technology is streamlining the prescription process by providing real-time, patient-specific cost information at the point of care. We explore how this system not only helps patients access more affordable medications but also streamlines the often cumbersome prior authorization process, reducing turnaround times from days to hours. Kyle shares insights on how their solution benefits multiple stakeholders in the healthcare ecosystem, from providers and patients to health plans and pharmacy benefit managers. Join us for an enlightening discussion on the future of digital prescribing, medication management, and how technology is being leveraged to enhance trust between patients and providers. Key Points: ArriveHealth's core offering: Real-time benefit network for e-prescribing workflows Company growth: Doubled in size from a revenue perspective in the past year How ArriveHealth's technology works:    - Provides real-time, patient-specific cost information at the point of prescribing    - Suggests lower-cost alternatives for medications and pharmacies    - Streamlines the prior authorization process Benefits for various stakeholders:    - Providers: Reduced administrative burden, improved workflow efficiency    - Patients: Lower medication costs, improved adherence, better healthcare experience    - Pharmacists: Cleaner scripts, fewer callbacks    - Insurance companies/PBMs: Cost savings, reduced administrative work Integration with major EMR systems (Epic, Cerner, Athena, eClinicalWorks) Partnership with GoodRx for additional cost-saving options Success metrics: Switch rates more than twice the industry average Future developments:    - Automating downstream processes (e.g., prior authorizations)    - AI-driven adherence tool for patient-provider communication ArriveHealth's mission: Reintroducing consumer choice in healthcare and leveraging trust between patients and providers Quotes: "We measure success by how often they accept that. And we're seeing switch rates that are more than twice the industry average." - Kyle Kiser on measuring the impact of ArriveHealth's recommendations "The most powerful leverage point to solve problems in healthcare is the trust that exists between patients and providers." - Kyle Kiser on the importance of trust in healthcare Kyle's Bio: Kyle is Chief Executive officer at Arrive Health, the leader in delivering real-time cost and coverage data to decision-making workflows. In his role, he focuses on helping providers and care teams improve patient access, affordability, and outcomes while reducing administrative burden. By partnering with health systems, health plans, IT vendors, and pharmacy benefit managers, Arrive health enables transparency and better patient care nationwide. Since 2013, Klye has helped grow the company from a vision to a reality, and has been at the forefront of some of the most transformational initiatives in healthcare. In particular, he has focused on projects that enable informed decision-making. His focus on interoperability has allowed partners to improve provider workflows and reduce medication costs for millions of patients. Kyle has helped develop incentive strategies for a country's most innovative employers and led product launches with the nation's largest payers. Prior to Arrive Health, he was a senior leader at Welltok, Catapult Health, and Principal Wellness Company.  Find Kyle: Arrive Health Website LinkedIn Connect With Us: Thriving Practice Community Be a Guest on the Show Schedule Strategy Session with Tracy Tracy's LinkedIn Business LinkedIn Page

L'actu culture-média de ce vendredi 14 février: L'acteur français Gilles Lellouche se verra décerner un Magritte d'honneur lors de la 14ème cérémonie des récompenses du cinéma belge le 22 février prochain L'artiste Miet Warlop va représenter la Belgique à la biennale de Venise l'année prochaine L'auteur dessinateur de bande dessinée Bastien Vivès sera jugé en mai prochain pour diffusion d'images à caractère pornographique de mineurs Scarlett Johansson appelle à mieux encadrer l'intelligence artificielle après la diffusion d'une vidéo truquée Merci pour votre écoute N'hésistez pas à vous abonner également aux podcasts des séquences phares de Matin Première: L'Invité Politique : https://audmns.com/LNCogwPL'édito politique « Les Coulisses du Pouvoir » : https://audmns.com/vXWPcqxL'humour de Matin Première : https://audmns.com/tbdbwoQRetrouvez tous les contenus de la RTBF sur notre plateforme Auvio.be Retrouvez également notre offre info ci-dessous : Le Monde en Direct : https://audmns.com/TkxEWMELes Clés : https://audmns.com/DvbCVrHLe Tournant : https://audmns.com/moqIRoC5 Minutes pour Comprendre : https://audmns.com/dHiHssrEt si vous avez apprécié ce podcast, n'hésitez pas à nous donner des étoiles ou des commentaires, cela nous aide à le faire connaître plus largement.

Join Bret and Amanda Brummitt in this inspiring episode of Generous Impact as they sit down with Matt Vestal, co-founder of Junction Health. Discover how Junction Health is making a significant difference in the healthcare landscape by establishing infusion centers within Federally Qualified Health Centers. These centers aim to provide much-needed life-promoting infusions to patients who face financial barriers in accessing traditional healthcare models. Matt Vestal shares his professional journey, starting from his early career at Cerner to co-founding Junction Health dedicated to serving underserved communities. Dive deep into the challenges and triumphs of operating infusion centers, the importance of the 340B pharmacy program, and how Junction Health is successfully partnering with federally qualified health centers to address healthcare access constraints. Listen in to hear stories that depict the real-life impacts of Junction Health's innovative approach, which not only delivers critical medications to patients in need but also injects vital revenue into health centers that serves the community. Discover the collaborative and compassionate culture fostered by Junction Health's team, determined to bring meaningful change to the world of healthcare. Learn more at Junction-Health.com.  

Nick Orser, General Manager at Verato, highlights the importance of trusted identity data in the healthcare industry and how master data management can help healthcare organizations deliver personalized patient experiences. The proliferation of data sources and health record systems makes maintaining a single, accurate view of each patient challenging. The MDM technology can help healthcare organizations access patient data across multiple systems to improve care outcomes and provide effective analytics and population management tools.   Nick explains, "To summarize what I'm talking about here, despite EHR consolidation with many organizations choosing to go all Epic or all Cerner, despite health system consolidation where organizations are buying up hospitals and physician practices like crazy, there's now this challenge in the industry that is 10 times harder today than it was just a decade ago." "The challenge is that dozens of these new applications in which a patient's data might be stored that an organization needs to tie together and unify. That data spans numerous clinical encounters, but now, there are marketing applications, digital applications, call centers, joint ventures, telehealth, and home health portals. And it's not just the number of applications that's really hard. It's the fact that my data as a patient might be represented differently across each application. In fact, 30% of stored patient identifying data is out of date, incorrect, or incomplete, making it hard to identify the same patient's data across all these different touch points because patients move and change their address. They get married and change their names, fill out a web form and provide only their email address, and schedule an appointment for a call center that mistypes their birthdate."  #Verato #HealthData #MasterDataManagement #WhoisWho #PtExperience #AIinHealthcare #PatientInformation verato.com Listen to the podcast here

Nick Orser, General Manager at Verato, highlights the importance of trusted identity data in the healthcare industry and how master data management can help healthcare organizations deliver personalized patient experiences. The proliferation of data sources and health record systems makes maintaining a single, accurate view of each patient challenging. The MDM technology can help healthcare organizations access patient data across multiple systems to improve care outcomes and provide effective analytics and population management tools.   Nick explains, "To summarize what I'm talking about here, despite EHR consolidation with many organizations choosing to go all Epic or all Cerner, despite health system consolidation where organizations are buying up hospitals and physician practices like crazy, there's now this challenge in the industry that is 10 times harder today than it was just a decade ago." "The challenge is that dozens of these new applications in which a patient's data might be stored that an organization needs to tie together and unify. That data spans numerous clinical encounters, but now, there are marketing applications, digital applications, call centers, joint ventures, telehealth, and home health portals. And it's not just the number of applications that's really hard. It's the fact that my data as a patient might be represented differently across each application. In fact, 30% of stored patient identifying data is out of date, incorrect, or incomplete, making it hard to identify the same patient's data across all these different touch points because patients move and change their address. They get married and change their names, fill out a web form and provide only their email address, and schedule an appointment for a call center that mistypes their birthdate."  #Verato #HealthData #MasterDataManagement #WhoisWho #PtExperience #AIinHealthcare #PatientInformation verato.com Download the transcript here

HighlightsCustomer Boldness (00:21)In previous keynotes, Catz has encouraged customers to be more bold – and customers are responding to that. Oracle's cloud business is growing at a rate of 50% a year. “More and more of our customers are willing to not only jump in with one foot but their entire bodies because they're getting more comfortable and they're also seeing that competition is moving,” Catz says.“Transformation and transforming yourself and modernizing yourself, that is not a destination; it's a constant journey.” Businesses are recognizing that they become more adaptable to meet customer expectations when they embrace these new technologies.Multi-Cloud Agreements (04:25)Multi-cloud agreements with Microsoft, Google Cloud, and AWS kicked off in 2024. “We have always believed that the customer should get to choose what they want to use and what environment they want to run in and how to really advance their agenda,” Catz expresses. Oracle doesn't believe in building walls or trapping customers; being open to this idea is central to Oracle's success. Because Oracle Cloud has different capabilities, the company has been able to collaborate with other providers to make their offerings work together to best meet customer needs.Healthcare Industry Offerings (08:55)Oracle has put extra energy into its industry suites, particularly for the healthcare industry. It aims to be able to handle everything from clinical trials to inventory to nursing schedules and more. At a recent health summit, Oracle launched new AI-powered capabilities for healthcare. While the company competes in several industries, Oracle acquired Cerner because “we knew that we needed to bring healthcare into the 21st century.”Larry Ellison previously shared that “we can't do it alone.” This means partnering with customers and being open to partner with other companies to apply their capabilities to ensure a quality customer experience is being delivered for patients, doctors, administrators, and others in the healthcare industry. “Do more, spend less doing it – that's our job, to give them that ability,” Catz summarizes.Revenue Goals (17:06)At its financial analyst meeting last fall, Oracle released its vision for $100 billion in revenue a few years out. Catz describes what that will look like within Oracle and how customers will contribute to the company achieving those figures. “We're telling you now, every year is going to be bigger and accelerating more,” Catz says. “The way that that curve works – it's almost unstoppable once it starts.”Cloud Data Centers (22:30)Oracle has been developing cloud data centers that are “small enough to go on a ship” as well as what Ellison has called the world's largest data centers, Evans notes. This will be important to Oracle customers in the coming years and beyond because “it gives them flexibility,” Catz explains. “We can start at any size and expand as they need it.”Ellison and New Products (24:59)2024 was a busy year for Ellison and 2025 will continue in the same manner. “This fellow does not rest,” Catz says. The Oracle team loves the new capabilities and new product lines that they've been rolling out to customers that there are no signs of slowing down.

In September 2023 when Billings Clinic and Logan Health merged to form one of the area's largest healthcare systems, one of the first orders of business for Justin Ott – a long-time IT executive at Billings who became CIO of the newly combined health system – was determining the organization's go-forward EHR. Prior to the […] Source: CIO Says Infusion of Oracle Tech Gave Cerner Needed Shot in the Arm: Now Well Positioned for AI-Powered Innovation     on healthsystemcio.com - healthsystemCIO.com is the sole online-only publication dedicated to exclusively and comprehensively serving the information needs of healthcare CIOs.

Send us a textDr. David Feinberg, M.D., is Chairman of Oracle Health ( https://www.oracle.com/health/ ), where he and his team are committed to making healthcare more accessible, affordable and equitable, building an open healthcare platform with intelligent tools for data-driven, human-centric healthcare experiences to connect consumers, healthcare providers, payers, and public health and life sciences organizations.Dr. Feinberg's work advances thought leadership and strategy related to unleashing the healing power of data through an open and connected healthcare ecosystem. Previously, Dr. Feinberg served as president and CEO of Cerner, now Oracle Health, where he led teams delivering tools and technology to execute on this strategy of improving the patient and caregiver experience. As a pediatric psychiatrist, Dr. Feinberg built his early career around helping children and families. He served as president and CEO of both UCLA Health and Geisinger Health prior to assuming leadership of Google Health in early 2019. Dr. Feinberg began his career at UCLA, researching and publishing in the areas of addiction and attention deficit hyperactivity disorder. He took on additional leadership responsibilities, including becoming the Medical Director of the Resnick Neuropsychiatric Hospital. Dr. Feinberg earned his M.D. from Chicago Medical School in 1989, finishing at the top of his class and is a member of the Alpha Omega Alpha Medical Honor Society. He also holds an economics degree from the University of California-Berkeley and an MBA from Pepperdine University.#DavidFeinberg #OracleHealth #Oracle #LarryEllison #GoogleHealth #GeisingerHealth #UCLAHealth #ElectronicHealthRecords #EHR #ClinicalDigitalAssistant #PediatricPsychiatry #SocialDeterminantsOfHealth #ArtificalIntelligence #MentalHealth #AgingInPlace #DigitalHealth #FoodPharmacy #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show

La journaliste Véronique Mortaigne publie « Brésils, Éloge de la déraison », une traversée ébouriffante d'un pays et d'un peuple, habile à s'extraire du chaos. « Qu'est-ce que le Brésil ? ». Une amie me répond, sans hésitation : « La plage ». Elle n'a pas tort. Jamais ennuyeuse, la plage au Brésil est un lieu unique. Neuf mille deux cents kilomètres de rivages, du sable blanc, ocre, doré, des baies, des îles, des caps, des lagunes, des estuaires, des falaises, des mangroves, de la boue, des récifs, des piscines naturelles. Le Brésil a été béni des dieux. De plein de dieux, noirs, blonds, catholiques, le tout fusionné avec les orishas, les divinités vaudoues, et agrémenté de la cosmologie indigène. La multitude de saints, d'anges, d'entités cosmiques, nourrit un mysticisme ardent.« Mais qu'est-ce qu'être Brésilien ? Un mélange de charme, de sensualité, de pouvoir d'attraction, de capacité à créer des situations bordéliques et enchantées. Cerner le caractère profond de ce peuple expérimental en perpétuel mouvement n'est pas une mince affaire. Antônio Carlos Jobim eut un jour cette formule : « Le Brésil n'est pas un pays pour débutants. Amateurs s'abstenir. »Dans ce récit guidé par le hasard, la quête du mystère, du secret et de la magie, Véronique Mortaigne nous invite à découvrir les expériences les plus folles et les plus improbables qu'elle a vécues (Joao Gilberto…), en profondeur, rencontrer un peuple habile à s'extraire du chaos. Plus qu'une déclaration d'amour, cette traversée ébouriffante à travers un Brésil multiple est un éloge de la déraison dans un monde qui étouffe.Véronique Mortaigne est journaliste, longtemps critique musicale au Monde, elle est l'auteure de plusieurs ouvrages (sur Césaria Evora, Manu Chao, Johnny Hallyday, Bernard Lavilliers, Anne Sylvestre) avec une passion particulière pour le Brésil où elle fut professeure de français à Récife (Nordeste brésilien).Playlist de Véronique Mortaigne- Maria Bethânia Ultimo Desejo, extrait de Maria Bethânia Canta Noël Rosa e outras raridades 1965- Caetano Veloso Falso Leblon, extrait deZii e Zie 2009- Luiz Gonzaga Vem Morena, extrait de Gonzagão olha pro céu 1949- Beth Carvalho Vou festeja, extrait deFirme e forte no pagode 1978.X - Instagram (vmobr23) Équateurs. Pour aller plus loin, quelques liens :- Véronique Mortaigne dans Le Monde - Entretien avec le photographe Pierre Verger en 1992.

La journaliste Véronique Mortaigne publie « Brésils, Éloge de la déraison », une traversée ébouriffante d'un pays et d'un peuple, habile à s'extraire du chaos. « Qu'est-ce que le Brésil ? ». Une amie me répond, sans hésitation : « La plage ». Elle n'a pas tort. Jamais ennuyeuse, la plage au Brésil est un lieu unique. Neuf mille deux cents kilomètres de rivages, du sable blanc, ocre, doré, des baies, des îles, des caps, des lagunes, des estuaires, des falaises, des mangroves, de la boue, des récifs, des piscines naturelles. Le Brésil a été béni des dieux. De plein de dieux, noirs, blonds, catholiques, le tout fusionné avec les orishas, les divinités vaudoues, et agrémenté de la cosmologie indigène. La multitude de saints, d'anges, d'entités cosmiques, nourrit un mysticisme ardent.« Mais qu'est-ce qu'être Brésilien ? Un mélange de charme, de sensualité, de pouvoir d'attraction, de capacité à créer des situations bordéliques et enchantées. Cerner le caractère profond de ce peuple expérimental en perpétuel mouvement n'est pas une mince affaire. Antônio Carlos Jobim eut un jour cette formule : « Le Brésil n'est pas un pays pour débutants. Amateurs s'abstenir. »Dans ce récit guidé par le hasard, la quête du mystère, du secret et de la magie, Véronique Mortaigne nous invite à découvrir les expériences les plus folles et les plus improbables qu'elle a vécues (Joao Gilberto…), en profondeur, rencontrer un peuple habile à s'extraire du chaos. Plus qu'une déclaration d'amour, cette traversée ébouriffante à travers un Brésil multiple est un éloge de la déraison dans un monde qui étouffe.Véronique Mortaigne est journaliste, longtemps critique musicale au Monde, elle est l'auteure de plusieurs ouvrages (sur Césaria Evora, Manu Chao, Johnny Hallyday, Bernard Lavilliers, Anne Sylvestre) avec une passion particulière pour le Brésil où elle fut professeure de français à Récife (Nordeste brésilien).Playlist de Véronique Mortaigne- Maria Bethânia Ultimo Desejo, extrait de Maria Bethânia Canta Noël Rosa e outras raridades 1965- Caetano Veloso Falso Leblon, extrait deZii e Zie 2009- Luiz Gonzaga Vem Morena, extrait de Gonzagão olha pro céu 1949- Beth Carvalho Vou festeja, extrait deFirme e forte no pagode 1978.X - Instagram (vmobr23) Équateurs. Pour aller plus loin, quelques liens :- Véronique Mortaigne dans Le Monde - Entretien avec le photographe Pierre Verger en 1992.

While at the Oracle CloudWorld conference, I had a chance to sit down with Seema Verma, Executive Vice President and General Manager at Oracle Health.  In this wide ranging interview, we cover a broad range of topics starting with her journey from CMS to now one of the leaders of Oracle Health.  Plus, she shares the vision for Oracle Health going forward. Given we're a couple years into Oracle Health's acquisition of Cerner, I wanted to check-in with Verma on the progress they've made merging Cerner into Oracle Health.  Plus, I ask her what long time Cerner users should know about what's happening at Oracle Health and what they can expect going forward.  She talks more about their new EHR and that more details will be shared at the Oracle Health Summit later this month. Learn more about Oracle Health: https://www.oracle.com/health/ Health IT Community: https://www.healthcareittoday.com/

Doug Rogers and James Kanary welcome Chris Vernaci, Senior Vice President of Growth and Commercial Sales at HART, a health tech startup. The conversation explores Chris's journey from large corporations like Cerner and Oracle to a smaller, agile environment at HART. They discuss the challenges of name recognition in the healthcare industry, strategies for targeting clients, and the importance of team culture and coaching in sales. Chris shares insights on learning from failure, managing expectations, and the future of healthcare data movement, emphasizing the need for seamless data integration to drive innovation in the industry.

Join us for an enlightening conversation with Dr. Craig Joseph, pediatrician and Chief Medical Officer at Nordic Global, as we explore the critical role of intentional design in healthcare technology. In this episode, we dive deep into how thoughtful implementation of Electronic Health Records (EHRs) and other digital tools can transform medical practices, improving both provider efficiency and patient care. Dr. Joseph shares insights from his extensive experience in healthcare IT and his book "Designing for Health," offering practical advice on making technology work for healthcare providers rather than against them. From tackling the challenges of "note bloat" to creating more intuitive user interfaces, we discuss innovative strategies to enhance workflows, reduce physician burnout, and ultimately create a more thriving practice.  In this episode, we discuss: The importance of intentional design in healthcare technology How to make Electronic Health Records (EHRs) more efficient and user-friendly The evolution of medical note-taking and the problem of "note bloat" Strategies for implementing technology changes in medical practices The balance between automation and human interaction in healthcare How to approach change management in healthcare settings The concept of "actionable alerts" in clinical decision support The impact of patient portal access on medical documentation Tips for streamlining workflows and improving practice efficiency The importance of focusing on outcomes rather than processes when implementing new technologies Key Takeaways: Intentionality is crucial when designing or implementing healthcare technology Good design can significantly reduce physician burnout and improve patient care Consider the end goal before reconfiguring existing processes into new technology Involve all stakeholders, including non-physician staff, in technology implementation decisions Balance automation with maintaining valuable human interactions in healthcare Thank you for listening to Thriving Practice! If you enjoyed this episode, please rate, review, and subscribe to our podcast.  Bio: Craig Joseph, MD serves as the Chief Medical Officer of Nordic Consulting Partners. He is a board-certified pediatrician and clinical informatician. Craig practiced primary care pediatrics for nine years before moving to Madison, WI to work for Epic. After seven years there, he served as Chief Medical Information Officer for several hospital systems using both Epic and Cerner electronic health records. At Nordic, Dr. Joseph works with hospitals and healthcare systems to help them improve clinician happiness and efficiency. He's recently co-authored a book about applying the principles of human-centered design to healthcare.  Find Dr. Craig Joseph: Website  Book Nordic Global Thought Leadership LinkedIn Connect With Us: Be a Guest on the Show Thriving Practice Community Schedule Strategy Session with Tracy Tracy's LinkedIn Business LinkedIn Page Thriving Practice Community Instagram

Oracle's Industry Cloud InnovationsThe Big Themes:AI integration in Industry Applications: AI, especially GenAI is playing a significant role in transforming industry applications. Mike explains how AI technologies are enhancing customer experiences, such as in healthcare, where they automate routine tasks and improve patient interactions. This integration is expected to continue growing.Shift towards Industry Suites: There is a clear shift toward adopting Industry Suites rather than piecemeal cloud solutions. Mike explains that Industry Suites, which integrate various technologies and services, are becoming more popular as they offer a cohesive solution and reduce the need for extensive regression testing and complex integrations. They help organizations maintain cloud benefits, such as innovation and security, without the drawbacks of fragmented systems.Business transformation through technology: Technology has a huge impact on broader business transformation. Mike notes that what starts as an IT project can evolve into a comprehensive business transformation initiative. For instance, AI-driven offerings in healthcare are not only improving operational efficiency but also transforming business models and patient care.The Big Quote: “Everybody's here to serve their customers. Patients are customers, people who check into hotels and customers, people who eat at restaurants or customers. Every CEO that I engage with says, 'This transformation helps me serve my customers better, and that's why I want to engage in it.'"

In this conversation, Nick Helfrich, Chief Growth Officer of Certify, shares his journey from starting in sales at Cerner to becoming a sales leader. He emphasizes the importance of being a student of healthcare, understanding the sales process, and knowing your territory and clients. Nick also discusses the transition from individual contributor to leader and the challenges he faced, such as flying at the right elevation and balancing tactical and strategic work. He highlights the significance of intentionality, data-driven decision-making, and involving the client in the sales process. Lastly, Nick talks about managing risk and uncertainty and the importance of having a process while adapting to the client's needs. Nick discusses the importance of communication, asking the hard questions, and training sales teams. He emphasizes the value of feedback and practice in creating a safe and effective sales culture. Nick also shares his approach to dealing with high growth expectations and the importance of data in driving sales success. He highlights the qualities of grit and perseverance as key attributes he looks for in potential hires.

This week, we revisited our interview with Darrell Johnson. Darrell has built expertise in the healthcare industry, identifying how data systems may be applied to improve patient outcomes, decrease healthcare utilization costs, and increase provider care delivery efficiencies. His passion centers on not simply bringing technologies to market but the successful implementation and utilization of these technologies within the entire healthcare system, including patients. He has utilized his marketing and business skills for over twenty years to identify and develop transformational business models across multiple healthcare industries, including pharmaceutical, capital equipment, implantable therapy devices, and medical software. Darrell is the Chief Strategy Officer at RLDatix, a global SaaS healthcare company aiming to improve quality, safety, and risk outcomes. Before RLDatix, Darrell spent three years as Cerner's first Chief Marketing Officer and the global EHR leader and twelve years in various leadership roles with Medtronic, the largest medical device company in the world. Darrell is passionate about driving brand leadership and usability experience. He built the world's largest remote monitoring system that has over 1.5 million lives being monitored across 78 countries, with strong evidence reflecting the impact on both clinical and economic outcomes. With his vision of engaging patients, his team also developed the world's first patient smartphone application for personal device management. His efforts consistently resulted in number-one brand positions globally. Prior to joining Medtronic, Darrell worked at GE Healthcare in Milwaukee, Wisconsin, for approximately eight years and held several key management and marketing positions. His data systems passion resulted in many firsts at GE Healthcare, including centralized remote monitoring, smart alarms, and a wireless digital portable x-ray technology. All of these technologies had significant value impact in improving clinical outcomes and improving care delivery efficiencies.  Darrell holds a bachelor's degree in economics and mathematics from the University of Minnesota and an MBA from the Carlson School of Management, University of Minnesota.

What is the MOSAIC-NLP project around structured and unstructured EHR data? Why is structured data not really enough for drug safety studies? And to what degree is NLP speeding up access to data and research results? We will learn all that and more in this episode of Research in Action with Dr. Darren Toh, Professor at Harvard Medical School and Principal Investigator at Sentinel Operations Center. www.oracle.com/health www.oracle.com/life  www.sentinelinitiative.org -------------------------------------------------------- Episode Transcript: 00;00;00;00 - 00;00;26;14 What is the MOSAIC and LP project around structured and unstructured data? Why is structured data not really enough for drug safety studies? And to what degree is NLP speeding up access to data and research results? We'll find all that out and more on this episode of Research in Action. Hello and welcome to Research in Action, brought to you by Oracle Life Sciences.   00;00;26;14 - 00;00;50;14 I'm Mike Stiles. And today our guest is Dr. Darren Toh, professor at Harvard Medical School and principal investigator at Sentinel Operations Center. He's got a lot of expertise in Pharmacoepidemiology as well as comparative effectiveness research and real-world data. So, Darren, really glad to have you with us today. Thank you. My pleasure to be here. Well, tell us how you wound up where you are today.   00;00;50;14 - 00;01;26;22 What what attracted you in the beginning to public health? Good question. So I trained in pharmacy originally, and I got my Masters degree in Pharmaceutical Outcomes Research at a University of Chicago, Illinois, Chicago. And it's where I first learned about a field called Pharmacoepidemiology, which sort of very interesting to me because I like to solve problems with methods and data and pharmacoepidemiology.   00;01;26;22 - 00;02;00;29 It seems to be able to teach me how to do that. So I got into the program at the Harvard School of Public Health, and when I was finishing up, I was deciding between staying in academia and going somewhere and getting a real job. And that's when I found out about an opportunity within my current organization and I've heard great things about this organization.   00;02;00;29 - 00;02;29;26 So I thought I would give it a try. And the timing turned out to be perfect because when I joined, our group was responding to a request for proposal for what is called a mini sentinel pilot, which ultimately became the sentinel system that we have today. So I've been involved in the Sentinel system since the very beginning or before we began.   00;02;29;28 - 00;03;02;25 And for the past 15 years I've been with the system and the program and because I really like its public health mission and I'm also very drawn to the dedication of FDA, our partners and my colleagues to make this a successful program. Well, so now here you are, a principal investigator. What exactly is the Sentinel Operations Center? What's what's the mission there and what part do you specifically play in it?   00;03;02;27 - 00;03;52;26 Sentinel is a pretty unique system because it is a congressionally mandated system. So the Congress passed what is called the FDA Amendments Act in 2007. And within that FDA, the Congress asked FDA to create a new program to complement FDA existing systems to monitor medical product safety and more specifically, the Congress, US FDA, to create a post-market risk identification and analysis system that will be using data from multiple sources that will cover at least 1 million lives to to look at the safety of medical products after they are approved and marketed.   00;03;52;28 - 00;04;33;07 So in response to this congressional mandate, FDA launched what is called a Sentinel initiative in 2008 and in 2009 as I mentioned, FDA issued its request for proposal to launch the Mini Sentinel Pilot program, and the program grew into the sentinel system that we have today. So it's for my involvement. It sort of grew over time. So when I joined, as I mentioned, we were responding to this request for a proposal and we were very lucky to be awarded the contract.   00;04;33;09 - 00;05;04;05 So when it was starting, I serve as a one of the many epidemiologists on the team and I led several studies and I gradually took on more leadership responsibility and became the principal investigator of the Sentinel Operations Center in 2022. So I've been very fortunate to have a team of very professional and very dedicated colleagues within the operations center.   00;05;04;05 - 00;05;27;26 So on a day to day basis, we work with FDA to make sure that we can help them answer the questions they would like to get addressed. And we also work with our partners to make sure that they have the resources that they need to answer the questions for FDA. And most of the time I'm just the cheerleader in chief just to share my colleagues and our collaborators.   00;05;27;28 - 00;06;11;23 Now that's great. And and then specifically, there's the Mosaic NLP project that you're involved with. What is that trying to achieve and what are the collaborations being leveraged to get that done? So Sentinel Systems has always had access to medical claims data and electronic health record data or year data. One of the main goals for the current sentinel system is to incorporate even more data, both structured and unstructured, into the sentinel system and to combine it with advanced analytic methods so that FDA can answer even more regulatory questions.   00;06;11;25 - 00;06;40;09 So the Mosaic and NLP project was one of the projects that FDA funded to accomplish this goal. So the main goal of this project is to demonstrate how billing claims and data from multiple sources when combined with advanced machine learning and natural language processing methods, could be used to extract useful information from unstructured clinical data to perform a more robust drug safety assessment.   00;06;40;11 - 00;07;21;18 When we tried to launch this project, we decided that we would issue our own request for proposal. So there was an open and competitive process, and Oracle, together with their collaborators, were selected to lead this project. So I want to talk in broad or general terms right now about data sharing, the standards and practices around that. It kind of feels silly for anyone to say it's not needed, that we can get a comprehensive view and analysis of diseases and how they're impacting the population without it.   00;07;21;20 - 00;07;46;15 NIH is on board. It updated the DMS policy to promote data sharing. You know, the FDA obviously is leaning into this. So is data sharing now happening and advancing research as expected, or are there still hang ups? So I think we are making good progress. So I think the good news is data are just being accrued at an unprecedented rate.   00;07;46;17 - 00;08;28;21 So there are just so much data now for us to potentially access and analyze. There's always this concern about proper safeguard of individual privacy. And through our work, we also became very appreciative of other considerations, for example, the fishery responsibilities of the delivery systems and payers to protect patient data and make sure that they are used properly. So you mentioned the recent changes, including in data management, ensuring policy, which I think are moving us in the right direction.   00;08;28;26 - 00;08;56;23 But if you look closer at the NIH policy, it makes special considerations for proprietary data. So I would say that we have made some progress, but access to proprietary data remains very challenging. And the FDA, the NIH policy doesn't actually fully resolve that yet. When you think about the people who do make that argument for limited data sharing, they do mostly talk about what you just said about patient privacy.   00;08;56;23 - 00;09;25;20 IT proprietary data. Pharma is especially sensitive to that, I would imagine. So how do we incentivize the reluctant how can we ease their risks and concerns or can we? Yeah, it's a tough question. I think that this require a multi-pronged approach and I can only comment on some aspects of this. So I would say that at least based on our experience, the willingness or ability to share data often depends on the purpose.   00;09;25;23 - 00;09;55;29 That is, why do we need the data? Many data partners participate in Sentinel because of its public health mission, and our consideration is how would the data be used again, Is there proper safeguard of patient privacy and institutional interest? There are other ways to share data. For example, instead of asking the data to come to us, we can send analysis to where the data is.   00;09;56;06 - 00;10;34;22 And that is actually the principle follow by federated system like Sentinel. So we don't pull the data centrally. We send an analysis to the data partners and only get back what we need it. And it's usually in the summary level format. So that actually encourages more data sharing instead of less sharing. I would say that recent advances in some domains, such as tokenization and encryption, might also reduce some concern about a data sharing, a patient privacy concerns in academic settings.   00;10;34;29 - 00;11;24;26 We've been talking a lot about days, for example, for individual who collect the data and the people I propose to offer them authorship or proper acknowledgment if they are willing to share their data. But that is not sufficient in many cases outside of academic settings. If you look at what is happening in the past ten years or so, there are now a lot of what people call data aggregators that are able to bring together data from multiple delivery systems or health plans, and they seem to be able to develop a pretty effective model to convince the data provider to share that data in some way.   00;11;24;29 - 00;11;55;28 And a way to do that could be to help these data providers to manage their data more efficiently or to help them identify individuals who might be eligible for clinical trials. More quickly. So there are some incentives that we could think of to allow people to to share that data more openly but personally, I think that scientific data should be considered public good and hopefully that will become a reality one day.   00;11;56;00 - 00;12;23;21 Yeah, that's really interesting because it sounds like it's both a combination of centralized and decentralized tactics in terms of of data sharing and gathering. Why is it so important to use unstructured data in pharmacoepidemiology studies? And does NLP really make a huge difference in overcoming the limitations and extracting that data? So in the past, I think that that's true.   00;12;23;21 - 00;12;58;07 Now, many pharmaco epidemiologic studies rely on data. They are not collected for research purposes. So we use a lot of medical claims, data that are maintained by payers. We use each our data that are maintained by delivery systems. So this data are not created for research purposes and much of this data, at least for claim, is data stored in structured format using established coding systems like ICD ten.   00;12;58;10 - 00;13;39;06 Coding system and structured data sometimes are not granular enough for a given drug safety study and certain data or set of variables that are required for claims reimbursements or other business purposes might not be collected at all. And people felt that, well, maybe the information that we need could be extracted from unstructured data because as part of clinical care, the physicians or nurse practitioner or the health care provider might include that information in the notes, but use user data also pretty messy, especially that unstructured data.   00;13;39;08 - 00;14;05;25 So instead of going through the unstructured notes manually to extract this information manually, technique by natural language processing could help us do this task much more efficiently so that we can mind a larger model of unstructured data. Well, obviously, when it comes to real world evidence, you're a fan. Tell us what excites you about using it to complement clinical research.   00;14;05;25 - 00;14;42;07 Get us more evidence based insights and help practitioners make better decisions. Yeah, that's a great question. Yes, I'm a fan of so I personally don't quite like the dichotomy between conventional, randomized, controlled trial and real world data studies because they actually sit along a continuum. But is true that conventional randomized trials cannot address all the questions in clinical practice.   00;14;42;09 - 00;15;30;17 So that's where real data and real data studies come in, because real data like we discussed come from clinical practice. So they capture what happens in day to day clinical practice. So if we are thoughtful enough, we will be able to analyze the data properly and generate useful information to fill some of the knowledge gap. The truth is we have been using real data throughout the lifecycle of medical product development for many years now, ranging from understanding the natural history or burden of diseases to using real data as controls for single arm trials, and that we have been doing this before the term real data became popular.   00;15;30;19 - 00;15;57;11 So I see real data to complement what we could do in conventional randomized trials. So real data studies don't replace clinical trials. I see them to be complementary, and real data studies sometimes are the only way for us to get certain evidence. We already talked about Mosaic and LP that project, but I kind of want to go a little deeper with it.   00;15;57;11 - 00;16;42;02 The idea is to tackle the challenges of using link data structured and unstructured at scale. Tell us about a use case for that project and why it was chosen for this project. We actually, Cerner proposed to use the association between Montelukast, which is an asthma drug and neuropsychiatric events as a motivating example. It is also important to note that the project is not designed to answer this particular safety question, because if you look at the label of Montelukast, there's also already a box warning on neuropsychiatric events.   00;16;42;02 - 00;17;18;26 So FDA already has some knowledge about this being a potential adverse event associated with the medication. The reason why or recalls is has proposed this project was because we actually did look at this association in a previous sentinel study that only used structured data, although the study provided provided some very useful information. We also recognized that certain information that we needed was available in such a data, but may be available in unstructured data.   00;17;18;28 - 00;17;42;18 So if we are able to get more data from unstructured data, we might be able to understand this association better. So that's why this motivating example was chosen. Well, this is an Oracle podcast and Oracle is involved in Mosaic, so I think it's fair to ask you about the technology challenges that are involved in what you're trying to do.   00;17;42;19 - 00;18;17;24 What does the technology have to be able to do for you to experience success? So Mosaic in LP is I was at a very ambitious project because it is using an LP to extract multiple variables that are important for the study. That includes the study outcome, which when you look at it, is a composite of multiple clinical outcomes and it's also trying to extract important covariates that could help us reduce the bias associated with real data study.   00;18;17;26 - 00;19;01;24 So I think technology comes in well is powerful in many ways. First, thanks to technology, the project is able to access very large amount of data from millions of patients who seek care in more than 100 healthcare delivery systems across the country. So this was hard to imagine maybe ten or 15 years ago. But now we have access to lots and lots of data at our fingertips because of advances in technology, because of the large amount and the complexity of the data methods side and LP becomes even more important.   00;19;01;26 - 00;19;33;19 And for this project, we are also particularly interested in whether an LP algorithm developed in one year trial system could be applied to another system, which has been a challenge in our field because each year our system is created very differently. So one, an algorithm that works in one system might not work in another. So we are hoping that through advanced methods and technology, we will be able to address this problem.   00;19;33;21 - 00;19;57;15 So without this technology advances, we might not be able to do this study as efficiently as we could all So the task might might not be possible. So where are we going with this? I mean, let's say the project is a success. What will that mean in terms of the FDA's goals and how NLP gets applied in medical therapeutics safety surveillance?   00;19;57;18 - 00;20;38;03 The hope is that Sentinel system can answer even more questions than it can address today. And the way that we are trying to accomplish that is to see whether or how this complex, unstructured data, we combine it with advanced analytic methods can help us answer questions that could not be addressed by structured data alone. I think through this project we also learned a lot about how the challenges associated with analyzing a very large amount of data from multiple sources.   00;20;38;06 - 00;21;11;14 Again, service data is compiled from more than 100 systems, so it is big but also very complex. And in many of our studies we really need that large amount of data just to be able to answer the question because we may be focusing on rare exposures or real come. So you really need to start with very large from our data just to get to maybe the ten patients that are taking a medication.   00;21;11;17 - 00;21;44;15 And what you learn with Mosaic, can that get applied to addressing other public health issues like disparate ease and asthma diagnosis and treatment, especially when you think about diverse groups? Yeah, that's a great question. So is the project is not designed to address these important questions, but if we are able to better understand the completeness of social drivers of health in these data sources, then we will be able to leverage this data to answer these questions in the future.   00;21;44;18 - 00;22;04;26 I think about how a project like this gets a evaluated at various steps along the way. I guess that's my question. How I mean, what what methods are used to ensure the validity of real world evidence? So the good news is in the past few decades we have been using real data, even though we might not be using the term.   00;22;04;28 - 00;22;36;22 So there's been a lot of progress in the field to improve the validity of Real-World Data studies. So we now have a pretty good framework to identify fit for purpose data, and we also have very good understanding of appropriate design and analytic methods. So to target trial emulation and propensity score methods. So this project and many other projects in Sentinel are following this principle.   00;22;36;24 - 00;23;14;03 And one thing to also note that this project is also following the overall sentinel principle in transparency. So everything we do will be in the public domain to allow people to reproduce, so replicate the analysis. So the protocol is available in public domain, and when we are done with the study, everything will be made publicly available. So that's one way to make sure that the the work at least is reproducible or replicable.   00;23;14;05 - 00;23;43;00 And through that process, we hope to be able to improve the validity of this study. And what about comparisons? How do you compare the results from different data sources like claims data, structured data? You know, I extracted unstructured data, all of that. How was that done, the comparisons? So if you're talking about the Mosaic and LP study, so we have a pretty structured approach to address that question.   00;23;43;02 - 00;24;13;14 So we are using this proven principle of changing one thing and keeping everything else fixed to see what happens. So the project will start by using only claims data to replicate the previously done Sentinel study. And then we are going to add on such data to see whether the results are different. And then we add on an LP extract that unstructured data one at a time to see whether the results change.   00;24;13;21 - 00;24;40;24 So by fixing everything else to be constant and changing one thing, we'll be able to assess the added value of each how data, both structure and structure. And that's how we are going to do it within the Mosaic and LP study. And then what about scalability? How would you make sure the NLP models that you develop are scalable and transportable across all these different health systems of which there are many?   00;24;40;27 - 00;25;10;10 Yeah. The question again is about transport ability. So one thing that is unique about this study, as we briefly discussed earlier, was that the the survey yesterday to actually come from multiple healthcare systems. So the end up models that we are developing will be trained in tune on a sample of patients from this system and not from a single hospital network.   00;25;10;10 - 00;25;42;18 So at the development phase, we are already taking into account the potential diversity of different delivery system. And as part of this project, we also include another delivery system to apply and test the method as part of the transport ability assessment. So we are doing that to make sure that the LPI models that we are developing for this project will be useful for other system as well.   00;25;42;20 - 00;26;12;29 Unknown There is a larger question about computational resources, so that will be the issue that would still need to be addressed because a train and tuning this and NLP models within such a huge amount of data requires a lot of computing resources. So that is something that we could only partially address in our study. But if we want to apply or do the same thing in our system, that would be something to consider.   00;26;13;02 - 00;26;43;13 We talked a little bit about the collaboration with your tech partner, but these things usually have so many stakeholders and disciplines and silos. Tell us first why collaboration is a good thing and unavoidable anyway, and then what the challenges of collaboration are. Maybe some tips on how to best make them work. The problems that we face, at least many of the problems that I face quite complex and they require expertise from multiple domains.   00;26;43;13 - 00;27;18;19 So that calls for collaboration from multiple stakeholders. And we always have our blind spots. So we only see things in a certain way and we always miss things. So that's why I think collaboration is important. But it's really hard sometimes because we all have our priorities and perspectives and sometimes they don't align. And I also learned throughout the years that we don't communicate enough and we may also not have time to communicate or we may be under pressure to deliver.   00;27;18;21 - 00;27;47;21 So all of that sort of contribute to the challenges of collaborating effectively, especially when you collaborate across disciplines, because we might be using different languages to mean the same thing or use the same term to describe different things. So even though we can all speak the same language less English, we might not be talking about the same thing and not communicate at all.   00;27;47;21 - 00;28;17;25 Because because we are using different joggers and terminology. So that has been tough. But I think we are getting better. And so I think that it is for us within the center of operation center, we try to communicate honestly and respectfully and we try to understand different perspectives and we try to find common ground. And but I think ultimately what brings us together is that we have a shared common goal.   00;28;17;27 - 00;28;44;17 A lot of the work that we do. So for music and NLP, we are all trying to answer the same question, which is that how do we use unstructured data and advanced analytic methods to answer safety question? So once we apply on this common goal, things become easier because we start to understand each other better or be able to communicate more effectively.   00;28;44;19 - 00;29;19;16 Just out of curiosity, what are the different stakeholders involved in Mosaic? Who falls on the roster? we have people from different disciplines, so we have experts in natural language processing and artificial intelligence. We have epidemiologists, both statisticians, clinicians, we experts in psychiatric conditions and respiratory disease. We have data scientists, we have engineers, we have project managers. So it's a very big group of individuals with different expertise in this project.   00;29;19;18 - 00;29;46;14 Well, you probably noticed Oracle's really thrown itself into and committed huge resources to health and life sciences. Things got really exciting with the acquisition of Cerner and Cerner and Visa. What's Oracle doing right and what do you think it should be doing to make itself even more valuable in health and life sciences? Well, this is a great but very difficult question, so I cannot comment too much what Oracle is doing or will be doing.   00;29;46;17 - 00;30;23;06 But I can say more generally that there have been a number of technology companies that have tried to foray into health or life sciences. I would say with mixed results. And one reason is that our health care system remains highly fragmented and complex, so it takes a lot of energy to break the status quo. So you probably know that we were one of the last countries in the world to transition from ICD nine to ICD ten coding system, and we are soon going to move into the ICD 11 system.   00;30;23;06 - 00;31;00;05 So I'll be interested to see whether the US is ready for that. And that again, is maybe a reflection of just how complex and fragmented our system is and disruptive innovation and I think are great, but they may or may not translate into successes when they applied to health care. That is not to say tempesta mistake. I'm actually pretty optimistic that the perspectives and solutions and ideas brought by technology companies could help us solve a lot of problems that we have today.   00;31;00;07 - 00;31;31;26 But I think that it will be good to engage people who will be struggling with these issues early on and to work together with them to develop solutions that are not just good on paper, but also feasible in practice. So at least in my very limited experience, we have seen some very cool technology that ended up not being useful for health care just because it's very hard to change what people have been doing.   00;31;31;28 - 00;31;56;09 So again, disruptive innovations are good, but sometimes it's just very hard to adopt, at least not quickly enough for for us to see meaningful changes. Yeah, that's really fascinating. It's, you know, it is disruptive innovation, but it's not always applicable to the to the goals you're pursuing. But it does feel like technology where that's concerned, the future is coming at us faster and faster.   00;31;56;11 - 00;32;32;21 So what are the technologies that are most interesting to you? Is it A.I. or what big advances in public health do you see coming? Maybe sooner than we thought. Yeah. Yeah. You know, I feel like you said some of this came too fast. Like, I wish I. And closer to retirement, I don't worry about this. But so even though I say disruptive innovation sometime might not work in health care, but I will say generative A.I. seems to be a recent exception.   00;32;32;24 - 00;33;10;14 So I would say that generative is definitely on the list of things that surprised me in a very nice way. I will also say that the continue fast accrual of better real data is also something that excites me and the continue recognition or increased recognition of the potential real data of. It's also something that I think is good to have for things that came sooner than I found it again, generative.   00;33;10;19 - 00;33;44;13 AI So if you ask me when, we'll be ready for generally. AI Last year or two years ago, I would say not yet, but now we in the era where everything seems possible. So I remain extremely optimistic about generative in some of these last language models that will help us analyze unstructured data even more efficiently. Well, therein it's deeply fascinating and exciting stuff.   00;33;44;14 - 00;34;10;27 Thanks again for letting me pester you with these questions. If our listeners want to learn more about Sentinel, Operation Center or Mosaic or you, what's the best way for them to do that? So Sentinel has a poverty website where we post everything that we do. So is Sentinel initiative dot org. So I am a member of the Department of Population Medicine at Harvard Medical School.   00;34;10;29 - 00;35;00;16 So our website's population is a thought, but these would be two places that would be very informative for audience. Who wants to know more? All right. We appreciate that. And to our listeners, go ahead and subscribe to the show. Feel free to listen to past episodes because they are free. There's a lot to learn here. And if you want to learn more about how Oracle can accelerate your own life sciences research, just go to Oracle dot com slash life dash sciences and we'll see you next time on Research in Action.

Zach welcomes old friend and CTO of Trualta, Shahzad Zafar on the pod today. Shahzad has always been interested in solving hard problems, which is what drew him to computer programming in the first place, and his family's background in medicine gave him a particular fascination with healthcare. He kicked off his career at Cerner and has been working within the intersection of healthcare and technology ever since. Today, Zach and Shahzad delve specifically into how #GenAI is transforming how physicians, nurses, and the healthcare team care for patients. Shahzad highlights successful use cases he's seen as well as areas to take caution in, driving home the importance of error control and risk mitigation. #GenerativeAI has already and will continue to change healthcare for the better going forward. Key takeaways include...  Enhanced Diagnostic Support: Generative AI improves patient care by providing advanced diagnostics, boosting efficiency, and enabling faster decisions. AI-Powered Chatbots: AI chatbots offer quick, accurate answers to patient queries and assist in scheduling, reducing provider workload. Early Detection and Prevention: Generative AI analyzes data for early detection of conditions like sepsis, potentially saving lives by predicting critical health issues. Personalized Caregiver Support: Generative AI offers personalized education and support, helping caregivers access relevant resources and training tailored to patient needs. Like, Subscribe, and Follow: YouTube: https://www.youtube.com/channel/UCAIUNkXmnAPgLWnqUDpUGAQ LinkedIn: https://www.linkedin.com/company/keyhole-software Twitter: @KeyholeSoftware Find even more Keyhole content on our website (https://keyholesoftware.com/podcast/). About Shahzad: Shahzad Zafar is a healthcare technology leader who enjoys building high-performing products and teams. He has over 18 years of experience and is currently the CTO at Trualta. He has worked with both public and private Cloud Platforms and has worked with a varying tech stack through the years, including C++, Java, Laravel, Ruby, Flutter, Javascript, MySQL and Oracle. Shahzad also actively speaks at various conferences across the country. Shahzad on LinkedIn: https://www.linkedin.com/in/shahzad-zafar-a482462/ 

Can cybercriminals paralyze a healthcare system with just a few keystrokes? Find out in this compelling episode of the Common Bridge, where Rich Helppie sits down with Dan Dodson, CEO of Fortified Health Security. We go beyond the headlines to explore the motivations driving cybercriminals to target healthcare institutions. With digital records and interconnected systems at the heart of modern healthcare, even a minor security breach can have devastating consequences. Dan sheds light on the urgent need for robust cybersecurity measures to ensure the integrity of patient care and protect sensitive data.Discover the pivotal role Managed Security Services Providers (MSSPs) play in defending healthcare organizations from relentless cyber threats. Through comprehensive risk analysis and 24/7 monitoring, MSSPs like Fortified Health Security develop customized strategies to mitigate risks and fortify defenses. Our conversation with Dan highlights the importance of deploying advanced technologies such as multi-factor authentication and air-gapped backups. The stakes couldn't be higher, and the complexity of maintaining strong cybersecurity is a challenge that healthcare providers must prioritize to safeguard patient information effectively.Join us as we tackle the shared responsibility of cybersecurity in the healthcare sector. Collaboration between health systems and technology providers like Epic Systems and Oracle's Cerner is crucial. Dan and I discuss the necessity for cybersecurity professionals to have a voice at the executive level and secure adequate funding. With cyber threats evolving daily, vigilance and ongoing education are paramount. From educating C-suite leaders to integrating cybersecurity into overall risk management, this episode offers practical advice for minimizing risks in an increasingly digital world. Tune in and stay informed about the latest trends and advancements in healthcare cybersecurity.Support the Show.Engage the conversation on Substack at The Common Bridge!

Episode 41 | Oracle's AI-Driven FutureThe Big Themes:Oracle's AI advancements: Oracle showcased rapid advancements in AI capabilities, introducing 50 new AI features, including generative AI models for tasks like creating job descriptions and email templates. It aims to ensure speed in innovation, with 25 of these capabilities specifically tailored for HR.Oracle's commitment to healthcare: Oracle is strengthening its focus on healthcare, moving its headquarters to Nashville, the epicenter of healthcare tech. Since acquiring Cerner in 2021, Oracle is working to integrate clinical, patient, and administrative systems into a seamless ecosystem. Its commitment extends beyond Cerner, as it tailors offerings for clients using Epic, enhancing workforce management, recruitment, and operational efficiency.Improving candidate experience: Oracle is enhancing the candidate experience with its latest updates to Oracle Recruiting Cloud. A new product line, Boost, aims to improve recruitment efficiency through AI-driven tools, offering candidates a more personalized and engaging application process. These advancements reflect a broader trend in the industry to prioritize not just customer and employee experiences, but also those of potential hires.The Big Quote: "I think [conference attendees] [are] really jazzed because of what the possibilities with AI are . . . what they were showing, in terms of AI, brought a new spring in their step."

About Stephanie Trunzo:Stephanie Trunzo is senior vice president for Oracle Health & Industries. While Stephanie is a tech geek across cloud, AI, and emerging tech, she is also a storyteller committed to usability and design thinking. This is reflected in the mission of Oracle Health: to create a human-centric healthcare experience powered by unified global data. Stephanie helped lead the launch of Oracle Health and was part of the core acquisition team working closely with Cerner, now part of Oracle Health.Stephanie's diversely skilled team continues to define Oracle Health's market presence, broadening the aperture of the traditional health landscape to a much richer and more holistic portfolio. That same holistic, unified model will be the pattern she will apply across other Oracle Industries.Previously, Stephanie applied her digital and experience disciplines to create and deploy Oracle's global, value-based approach for multi-cloud, hybrid customer strategies.Stephanie joined Oracle from IBM, where she was the global head of IBM Cloud Garage, a network of more than one dozen innovation hubs purpose-built to meld industry practices, startup culture, and IBM's expertise. Prior to that, she founded and led her digital transformation startup through a public acquisition of Globant.Stephanie was affectionately dubbed “the prototype” for the chief digital officer role by the CDO Club. She is an active board advisor, giving back to nonprofits and early startups, including Valeos, Oracle Health Foundation, International Science Reserve, and InsureLife.Her writing can be found in publications such as Fast Company, Forbes, and HuffPost.Things You'll Learn:Oracle Health's focus is on putting humans at the center of all decisions, with initiatives to streamline patient interactions and provide a more intuitive, seamless patient journey. Oracle is working on solutions to reduce the administrative burden for clinicians, empowering them to focus on care rather than data entry.The industry can facilitate tighter and more impactful collaborations by offering data sharing in an anonymized manner and bringing partners together. This approach ultimately drives innovation.While AI has been present for some time, Oracle Health is now leveraging it to create transformative impacts, which involve improving efficiency, streamlining workflows, and enabling intelligent, patient-focused interactions.Oracle is exploring the potential of large language models and Gen AI for novel disease prediction and personalized medicine.Resources:Connect with and follow Stephanie Trunzo on LinkedIn.Learn more about Oracle Health on their LinkedIn and website.

In this episode of Infrastructure Matters, hosts Steven Dickens and Camberley Bates cover the Rubrik IPO, Oracle's positioning in the cloud market, plus IBM's Storage announcements. Key topics covered:  Rubric IPO: Rubric, a data protection company, went public with a $5.6 billion valuation, emphasizing its scale-out data protection capability and its focus on cybersecurity. IBM Earnings and Acquisition: IBM reported solid earnings, with notable growth in software and hybrid cloud, and announced the acquisition of HashiCorp for $35 a share, enhancing its open-source support model. IBM Storage Announcements: IBM introduced Storage Assurance Perpetual, a program aimed at keeping customers' storage infrastructure current over an eight-year period, and unveiled enhancements to its virtualized storage product, SVC, focusing on replication and mirroring capabilities. Google Cloud Growth: Google Cloud's revenue surged 28% year-on-year, nearing $10 billion for the quarter, signaling strong sales execution and growth momentum in the enterprise market. Oracle Developments: Oracle showcased its Exadata platform's cloud connectivity and cost-effectiveness, positioning itself as a competitive player in the IaaS space. Larry Ellison's involvement highlighted the company's AI strategy and its integration with the Cerner acquisition for healthcare innovation.  

Read beyond the headlines! Support Local Journalism https://www.spokesman.com/podcastoffer

How can shifting mindsets fuel the next wave of innovation in the pharmaceutical and life sciences industry? In what ways can we ensure the vast amounts of health data are utilized securely and effectively to foster groundbreaking medical advancements? And how is Oracle's new Health Data Intelligence poised to transform the industry in an unprecedented manner? You'll learn all that and more with our guest Michael Fronstin, Vice President and Chief Commercial Officer at Oracle Life Sciences, who has worked across nearly every area of the industry from positions at Merck to J&J to Kantar Health and now at Oracle.   --------------------------------------------------------   Episode Transcript:   00;00;00;04 - 00;00;26;25 In what ways do the mindsets in the pharma industry need to change? How can we make sure massive amounts of health data is applied to practical effect? And how might Oracle's new Health Data Intelligence platform be an unprecedented game changer? We'll find all that out and more on Research in Action. Hello, welcome to Research in Action, brought to you by Oracle Life Sciences.   00;00;26;25 - 00;00;49;15 I'm Mike Stiles. And today we've got a guest who's been a veteran in the life sciences industry and who knows Oracle Life Sciences quite intimately because the guest is Michael Fronstin, vice president and chief commercial officer at Oracle Life Sciences. He's worked across nearly every area of life sciences, from positions at Merck to J&J to Kantar Health and now at Oracle.   00;00;49;15 - 00;01;11;25 So, Michael, thanks for being here. Thanks, Mike. Happy to be here and thank you so much for hosting this session. Really appreciate it. Great. Well, you know, you're the perfect person to talk to about what I want to talk about, which is changing people's minds and changing how we even approach and think about life sciences. So you've got that to look forward to.   00;01;11;25 - 00;01;34;28 But first, let's learn a little bit more about you. How did your interests and opportunities in life take you down the path that led you to where you are now? Yeah, thanks for that question. That's that's a great question to start out with. I'll tell you that as human beings, we all have something going on in terms of health care, whether it's impacting ourselves or friends or family, everyone's going through something.   00;01;34;28 - 00;01;56;25 At some point. You just don't know what the magnitude is or how long lasting, right? So having patience and empathy is so important. And of course myself, I've gone through things and unfortunately starting at a very early age of 12, I lost my best friend to the brain cancer and from the time I was 12 to the time I was 21, unfortunately, I lost a lot of people to different health ailments.   00;01;57;11 - 00;02;17;10 I guess, climaxing with losing my father when I was 21 years old. During that time, I always thought about health care and how it was impacting the people around me and wondering what could I do? And I felt pretty helpless, to be honest with you during those times, because some young boy don't there and there really wasn't anything I can do.   00;02;17;10 - 00;02;35;01 But as I got older and I went into college, I realized I could make a difference in health care. And that was going to be the industry that I was going to focus on. So I went into social sciences, became a sociologist with a business math background, and went to graduate school for an MBA in health care arbitration.   00;02;35;10 - 00;02;56;07 And that's when really things opened up to me where I started saying, okay, what aspect do I like? Where can I make a scalable impact? And I ended up joining Humana A down in Florida for a year or so, realizing that I can make a difference there and get people enrolled, help them get claims processed and paid. And from there my career took off.   00;02;56;07 - 00;03;21;02 I end up going to Merck, carried the bag and really experience the in office experience back in the days of the early nineties in terms of what patients were experiencing, seeing doctors who were really, really good and so much good at diagnosing patients and treating them in a time where most of the chronic conditions didn't have treatments available and new ones were coming out.   00;03;21;16 - 00;03;53;06 And I'll tell you, it was pretty exciting during these times being at Merck and seeing all these innovations. But I'll tell you, during that time I was really able to focus on one therapeutic area and it wasn't very scalable. It wasn't really having the impact it wanted. And it wasn't until I came to the consulting side of the business, you know, working with dozens of customers and maybe hundreds of brands over the past 20 plus years where I really felt like maybe a direct and indirect impact on people's lives around the globe.   00;03;53;28 - 00;04;16;02 So that's that brings me to today. And now I'm with Oracle Life Sciences, where I feel like it's even bigger and broader and better. So I'm excited about the present. I'm excited about the future. Yeah. You mentioned you kept repeating a phrase that kind of struck stuck with me, which is that you wanted to make a difference. Is that hard to do in the health care space?   00;04;16;02 - 00;04;39;12 I mean, have you been gratified by your ability to do that or has it always been a push and pull? Oh, interesting question. Definitely a push. And so, you know, sometimes you can you can make decisions and get them executed very quickly. Other times, it takes a while to do. You know, you have regulatory bodies that you have to deal with different types of payers around the world.   00;04;39;22 - 00;05;04;19 Decisions are always made quickly. And if it's the right decision because of various reasons, whether it's bureaucracy or internal or external, or you need to generate real world evidence modeling or even publications, we have more than 2000, maybe 3000 publications, and you develop the evidence, you submit the publication. It could take, you know, six months, a year, two years to get it published right?   00;05;04;19 - 00;05;24;14 So things just take time, unfortunately. But yeah, you can make a difference. I feel like I've made a difference. I feel pretty gratified about what I've done. And in the areas of the impact that I've made. So and a lot of it is just make an impact within your world and hoping that you can expand it beyond to make a broader impact.   00;05;24;14 - 00;05;59;11 You were at Kantar Health for like 17 years or so. How did what Kantar does align with Oracle Life Sciences and the idea behind just leveraging technology to benefit customers and partners? I'm actually coming on 19 years since we think about it and you mention it. So when I step back and think about my time at Bert or Change in Merck and the broader industry, life science clients need to accomplish three things in order to get their compound, whether new or existing compound, really the new compounds into the hands of the appropriate patients.   00;05;59;11 - 00;06;24;18 They need to get their drugs approved right by some regulatory authority. They need to get them reimbursed and they need to have a strong launch to drive awareness. Otherwise no one's going to prescribe it or patients. People aren't going to request it, right. So those three things need to need to occur. Kanter Health is really focused on the second and third in terms of the research services and expertise.   00;06;25;00 - 00;07;10;02 So the types of people are. Kanter Help are methodologies, social scientists like epidemiologists, psycho nutrition, these these are the folks that know how to design and conduct research, how to consult on the research from a Real-World evidence perspective and driving insights, evidence from a commercial planning perspective, prioritization, things like that. Where is the Oracle Life Sciences group? The other side of the group is really all about technology and applications predominantly focused on driving clinical trials for regulatory approval, of course, and in the area of pharmacovigilance during those trials and tracking them when those products are in the real world.   00;07;10;06 - 00;07;38;08 Right. Post-marketing authorization. So when you bring these two groups together and these types of people together, the technology, the medical intelligence, the scientific, methodological experience of the cancer health folks, have you got the best of all worlds, right? Technology, data experience combined. You take these wraparound services with the technology in and now our clients are able to see a much higher level of value, if you will.   00;07;38;23 - 00;08;02;25 Well, you've actually been anything but shy in the past about saying how the mindsets in the pharma industry really need to change. So what is the current mindset? And in what ways is it limiting? I'll tell you, the health care industry, including life sciences, has always been a little bit of a laggard in terms of of our movement.   00;08;03;11 - 00;08;30;15 Part of that issue is that we we operate in silos, right? And even within our life science clients or customers, the different cross-functional teams don't always come together. They don't know each other. Sometimes they buy the same data, right? So the inefficiencies of spending more budget than they need to, we're not leveraging the same data for different purposes, and we really need to break down the silos.   00;08;30;29 - 00;08;53;15 I think that from a mindset perspective, individuals on every side of the business really need to step back and pick up their heads and look around, see the big picture, understand where are we going? The data is critically important. Big data was becoming the buzzword ten, 15 years ago, but no one really knew what that B meant. Well, now it's here.   00;08;53;22 - 00;09;14;06 We could do something with big data, right? Is sort of on the fringe. Some people are using it, some people aren't, there hasn't. So this is a time where you could either bury your head in the sand because you don't understand it or you're afraid of it, or you can lean in and figure it out. And if you don't lean in, you're going to be left behind.   00;09;14;06 - 00;09;45;01 So I think we need to break down the silos. People need to step back and see the big picture. And I think they need to take risks and and lean in and it Oracle, that's what we're doing. We're committed to helping, you know, through creating open ecosystems, to breaking down barriers across teams, using our teams. And, you know, hopefully everybody will wind up picking your head up and looking at the big picture and caring more about collaboration and how these things can improve so that innovation moves forward faster.   00;09;45;17 - 00;10;06;25 Is that a realistic ask? I mean, I assume researchers are very busy with their heads down working on what they're working on. Can they can they expand and broaden their view? They have that luxury, Absolutely. It's like anything else, you just have to make the time. You got to take the time to make the time, invest the time to figure it out.   00;10;06;25 - 00;10;26;26 It's not easy. And I'm not saying it's easy by any means, but it's worth it to do. And I remember when I was a rep with Merck, you know, moving to Pennsylvania, the Home Office, the analysis, one of my problems that you get there and if you want pieces of advice when you get there, keep your head up.   00;10;27;13 - 00;10;51;11 And I said, I'm always positive. He said, that's not what he said. Look around, understand what's around you, incorporate it, immerse yourself in things you don't understand. You know, be comfortable being uncomfortable and again, new job, new new house placeholders. How do we find the time, how to figure it out? Right. And I see the people around me and our clients.   00;10;51;11 - 00;11;18;18 I see the people around me at Oracle Life Sciences. The ones who are doing that are the ones that are being most successful. Yeah, I love that. Get, get comfortable being uncomfortable. That's not something people dive into, as is uncomfortableness. But, you know, I don't care if it's industry, politics or even favorite flavor of ice cream. Getting anyone these days to change their mind or change their mindset is really hard.   00;11;18;18 - 00;11;49;09 So getting an industry to collectively think differently, that can't be easy. So what do you see as the biggest challenges to that? And is it that there needs to be some driving force for that? And is that the role Oracle's trying to play? Yeah, it's not easy for sure. All right. So some of the biggest challenges are really the cultures that are existing within and across the industry where people are so busy, right?   00;11;49;11 - 00;12;16;11 They're not set up to work. Cross-functionally The siloed nature that's that's occurring across our industry, even in between clinical care and clinical research, there are gaps. So I think all these different places are causing, you know, challenges in terms of making a difference, getting immersed and taking those risks. People aren't always rewarded for taking risks. So let's say it happens.   00;12;16;11 - 00;12;40;29 Let's say there's a shift in mindset and we're thinking more about leading with knowledge and information and looking at that big picture. What opportunities does that present for both the industry and for me when I get sick? Yeah, no, that's a great question as well. So for the industry, I think we'll be able to actually bring compounds to the to the marketplace more quickly.   00;12;41;10 - 00;13;30;00 Right. For you as an individual or us as individuals, all of us will be able to have more options, both clinical research as a care option. Right? Right now, only 3% of eligible patients participate in a clinical trial. Right. If we're able to take information and put it back in the electronic health record or h.r. System so that doctors can look at it at the point of care and make decisions whether it's about what is your care that they want to prescribe or it's about how are these products impacting you as a patient from a pharmacovigilance or really a tolerability or safety perspective, they're able to adjust very quickly right there on the fly, right?   00;13;30;00 - 00;13;51;29 They'll have more data at their fingertips, as we put it in. And that also could be recruiting patients into clinical trials. Right. So they don't know what's the inclusion exclusion criteria. Look it up. So how can you at their fingertips and knowing that this patient can just walk in the door for these patients scheduled to walk in this week, they're eligible.   00;13;52;00 - 00;14;12;02 Let me make sure that I talk to them about that so that they have other options that will help them get well. Yeah, So it's a good payoff. Your answer to this can be Mike, why don't you just mind your own business, but ask Oracle recently combined their Oracle Health and their Oracle Life Sciences divisions. Why did they do that?   00;14;12;11 - 00;14;37;06 Well, I'll tell you, I won't tell you to mind your own business. This is sort of the the biggest payoff I think we're seeing is movement that we've seen in health care. So the acquisition of Cerner by Oracle was just enormous. And it Cerner, these are your cancer health group is part of it really also was a big deal, right?   00;14;37;12 - 00;15;06;10 Because now we can take what's happening in health, in the clinic, in the hospital, in the offices and combine it with life sciences. Everybody has the same goal, which is to save lives or to increase quality of life of patients. But both of these groups, the hospital systems around the world and the life science companies around the world, they're not connected, right?   00;15;06;10 - 00;15;40;22 They want to be connected. They want to intersect, but they're working in silos, trying to influence each other when they both have the same goals, which is to save lives or help people. And now with Oracle Health and Oracle Life Sciences being under not only the same umbrella of Oracle, but under the same leadership in terms of team of firms, we're able to break down the silos so that we're able to share the appropriate data and information in an open equal ecosystem in bi directional way.   00;15;41;11 - 00;16;09;04 And while these two groups are deeply intertwined, yet this distinct, if you will, there are innovations there that we're looking at that will help everybody that some of the migrations celebrate recruitment, sharing of data, point of care decisions, things of that nature. So it's about turning data into information, that information into insights with some kind of open, intelligent, cloud based platform.   00;16;09;27 - 00;16;39;24 There is the problem, though, of drowning in data, but starving for insight that's applicable to so many businesses across so many industries. How would the ecosystem that you just described keep life sciences customers from drowning in data that is never used for practical effect? They're absolutely drowning in data. There are more data sources existing secondary data sources in the industry and across the world today.   00;16;40;05 - 00;17;12;02 The majority of these like probably 98% of them are not unified, they're not connected, and interoperability is lacking. Credit card companies figured it out a long time ago when healthcare has and we're starting to get there. Training unified platform of data Health data intelligence platform is what we call it in Oracle, backed by the Oracle cloud infrastructure. So you have data that's very sensitive sovereignty of nations, you're using it.   00;17;13;04 - 00;17;58;11 And of course OCI, Oracle Cloud Infrastructure affords the opportunity for security and speed and all these other benefits. So the more of tokenization we could do to connect the charged with other h.r. Claims with patient reported outcomes survey. The more we can do that in standardized ways with the right governance will help our clients sort through this sea of information so that we can and will help them, of course, you know, focus on what's important, you know, and use A.I. to define the trends in predictive analysis, what predicts better or worse outcomes.   00;17;59;01 - 00;18;21;22 So it's going to take time. We're getting there. We're already making a lot of progress, but I think that's now how we're going to help our clients get there. Well, I did ask about the obstacles of changing overall mindsets, but what are the remaining obstacles to actually building and implementing this eco system that you're talking about? Are there remaining tech obstacles?   00;18;21;22 - 00;18;50;01 Are there privacy issues? I mean, what's what's there that's making this a tough job? Not only we drowning in data, we're drowning in obstacles like that. So certainly you know, that's an obstacle of legalities around the world. Cultural changes and mindsets. Like we mentioned, there's governance. Who owns the data? We get data right to the data technology. Then we go back to that for a second.   00;18;50;11 - 00;19;13;28 You know, how do we connect from one system to the other? I do believe there's still 300 EHR systems out there. The interoperability, governance image. I mean, we're just not sure about. Also, we got to kick them off one at a time. And you know what we're doing at Oracle and Oracle Life Sciences is we're partnering with a lot of different organizing that's out there.   00;19;14;06 - 00;19;50;17 You might have seen our partnerships with the video code here. Johnson Labs, from algorithms, Perspectives. We're partnering with a lot of other organizations to help chip away at these obstacles and get to this ecosystem that we're talking about, where everybody wants. Yeah, you know, when you when you list those obstacles, one thing that's not there is resistance by patients, because I think most of us, you know, it's kind of a joke amongst everybody how every time you go to the doctor, you fill out the same forms again and again and again and again.   00;19;50;27 - 00;20;14;15 Clearly, there's not any kind of centralized clearinghouse for data on me as a patient. And I think most of the public kind of What's that? What's your view on meeting patient expectations where that's concerned? You know, isn't that the most important thing right of the whole conversation is putting the patient at the center of meeting their expectations. Okay.   00;20;14;15 - 00;20;41;03 There are a couple of countries where this is already occurring with the patients. The is all in one place. The patient just pulls up their app and they go and it doesn't matter which doctor or hospital you're walking into or what country they're visiting when they're traveling, they have their medical records in their pocket. One of the articles of issues is around privacy, and you might have mentioned this.   00;20;41;16 - 00;21;12;16 So in the US we have hip in Europe yard and this is trying to protect the patient for the right reasons. But we have to and we have to work within these systems to make sure we're able to operate together for the patients. There's nothing more annoying walking at your doctor's office and filling out the same or complaint or consent form or insurance form or whatever it is, you know, and it's certainly something that we need to do.   00;21;13;04 - 00;21;46;07 I think from a cohort perspective, the older populations and I'm not sure where that likes it's at 40 or 50 or 60, I think they're a little bit more protective and reticent about their privacy and their information. Whereas I see the younger generations, they're like, it makes sense to share it all the time. I wanted out less concerned about privacy, and maybe it's because of how they've grown up with the apps, social media, you know, everything's out there, you know?   00;21;46;08 - 00;22;09;17 So I think the trend is here and the tide is turning. You know, we have to find ways to continue to meet the patients and people where they are. Well, I'm sticking with that patient theme. There's how patients are involved or not in research. And we are hearing more about patient centered outcomes in research. It's another kind of mind shift that needs to happen.   00;22;09;17 - 00;22;35;04 How are we moving toward that where we're listening to the patient more and involving them more in clinical research than we used to? And that's that's the next great question. You threw that statistic out there that what, there's like 30% participation? I mean, there's clearly an issue. Yeah, Yeah, for sure. So patient reporting outcomes are typically subjective nature, right?   00;22;35;04 - 00;23;06;29 So by developing different instruments and scales that derive or predict something in might predict undiagnosed insomnia or anxiety, depression might predict of control of asthma, things of that nature. But there's typically surveys that have been validated through different types of behavioral science, a cognitive interviewing techniques, things of that nature, and then putting them out there. Right. And there's pros and there's observables, which are caregivers, right?   00;23;06;29 - 00;23;33;29 So someone caring for an adult relative, they're scales like that around caregiver burden, these sorts of things. And I'll tell you that the FDA has made a concerted effort to focus on patient focused drug development, and they've put these guidelines out there in terms of what they expect as websites companies are going through their clinical trial or clinical development programs.   00;23;34;00 - 00;24;01;17 Right. So I think that was a really great step to say not only open to this, we want it, we expect it. Right. So we've seen some of that, too. Now get your question. How do you do it right. Well, you can go with it. You charge it claims and look at information about the patient. But you also need to go directly to the patient and get their voice so you can do qualitative types of exercises.   00;24;02;04 - 00;24;22;21 For us at Oracle, I think this live of voices two trials where we go out to cohorts of patients who are eligible and we run through issue friendly terms the inclusion exclusion criteria. What do you think? Would you participate or not? What do we need to change here? And there's a whole bunch of other things to expose them to.   00;24;23;04 - 00;24;46;07 And then they tell us just no way, and this is impacting them. Phone calls of various clinical trials that our clients are working on, and they're taking it back to the EMA, the FDA, and say, here's the patient's voice and this is why we're making the decisions so that we're representing what these patients want in our trials. And often it's different.   00;24;46;23 - 00;25;13;08 So that that's one way We're also seeing more decentralized clinical trials. So over the past four years, with all the challenges of leaving one out and going to a site DCT decentralize, some trials have really accelerated in terms of the volume of trials. So so no longer just a patient have to drive an hour or 4 hours or however far to a site.   00;25;13;21 - 00;25;41;10 Now you bring the trial to them. You bring the phlebotomists to their house, you send them the wearable technologies or whatever it is they might need. So you're meeting the patients where they are so that you could increase participation and be more efficient, more productive, and really get it done in a better way. And the last thing I might mention is some natural history of disease registries.   00;25;41;21 - 00;26;07;25 These are registries that occur usually before the product goes into phase two or phase three clinical trial. And this is where you really start to understand what is the natural history of the disease. Most important, rare diseases where it could take years and years to get a count out in development compounded through or me to diagnose the patients.   00;26;08;04 - 00;26;33;01 And it takes too long to do that. So understanding the natural history of disease is critical. Right now we're running a global registry called Guardian, which is in Gauci Disease type two and Type three, and this registry is the Guardian Registry Registries one. We're collecting patient and caregiver information. We're actually developing a new approach and a new ops or so.   00;26;33;01 - 00;27;04;27 We'll have the patients voice. There are no products indicated for type two or Type three. So all the information is being fed back to the clients who have compounds in development for consideration in their clinical trials. And we're working with the International Gaucher Alliance, which is the global patient advocacy group on this registry. So it's a great partnership and it's getting that patient's voice, you know, where it needs to be, which is in the hands of of the compound development.   00;27;04;27 - 00;27;29;14 You mentioned A.I., you touched on that a little bit at AEI has certainly become part of the conversation, thinking about how it is or has the potential to impact therapeutic research and development. What, in your view, is and isn't overhyped about A.I. and the different stages of research and getting drugs to market so much? I make a lot of a lot of hype.   00;27;29;20 - 00;28;10;01 But also there's there's a lot of there's a lot of sizzle and there's a lot of sauce, right this. So you have to look for it and find it. So reading articles about organizations like Genentech and Janssen who are doing what's called Lab in the Loop, right. And a lot of a lot of life science, pharma companies and biotechs are doing this now where they're doing a and they're crossing their existing and other contacts with biological databases to uncover where might there be a match where some combination of a compound or multiple compounds could actually influence some disease?   00;28;10;01 - 00;28;47;05 Right. And then they tested they put it back in. So that's one area where we're seeing a lot of activity with with a for sure, critical trial designs, just looking at feasibility and protocol optimization and to understand where are the patients, how we are and how they're helping with patient recruitment. Where is indentify sites identifying the patients and incorporating dashboards back at the sites to help doctors identify and quickly recruit those eligible patients, or at least to have the conversations to see if they're interested.   00;28;47;14 - 00;29;28;22 Understand diversity of disease using various databases that have social determinants of health to make sure that we're diverse. Once the FDA is draft guidances, which which looked at everything from social determinants and ethnicity to co-morbidities, other demographics, transplantation, patients, etc., etc., etc. real world evidence teams are using it for their literature reviews. Unfortunately, sometimes they come across hallucinations or some false references, you know, show up and therefore you're always going to need this human collaboration to make sure your data is reliable.   00;29;29;03 - 00;29;55;07 And I'd say the last thing my head is pharmacovigilance, where we can go into existing databases, e charts, claims, both structured or unstructured notes, I should say, you know, and pull out information to identify patients who are having issues and report it in some sort of rapid or real time reporting and not wait. So out a major issue?   00;29;55;19 - 00;30;18;15 Well, since the listeners have been interested enough to still be listening, let's reward them by diving deeper into some of those specific technologies for clinical trials. What is Oracle's role in helping with randomization and trial supply management, which I think is also known as interact of response technology? Again, the work being done to that to get to therapeutic breakthroughs faster.   00;30;18;27 - 00;31;04;00 Yeah. Or TSM randomization, trial or supply management and ERP. It used to be called priority and now it's our TSM. This is an area where we've been playing for a long time. Continue to look at our tools for our clients so that they're able to do things that are quicker, faster, more efficiently. And certainly we've invested in a number of new people around the organization in our data product team, which is made up of some phenomenal engineers, you know, and they're investing we're investing significantly in our technologies to bring it to the next level and clients are responding appropriately, which is which is great.   00;31;04;03 - 00;31;30;08 And it's in a scenario where it's going to help clinical trials more quickly and more efficiently. So amazing things are happening. But, you know, I'm never satisfied. So I'm always curious about what the future could hold. I mean, we already touched on A.I., but what trends and technologies are you seeing out on the horizon that are most likely to bring us the kind of health care revolution that we think is possible?   00;31;31;11 - 00;31;55;06 Well, we've talked about some of them, this change in thinking culture for sure. Some of the policy and privacy types of things that we need to to get through. But this is what's not only on the horizon, but is here, right? It's here right now. I'm excited about the things that we're doing with Oracle Life Sciences to get there faster.   00;31;55;18 - 00;32;30;27 You're combining the data, our medical intelligence for our clients, just seeing it all in one place so that our customers are able to leverage it in a way, giving back to a future for physicians to close that gap between clinical research and clinical care. I think that's what I'm most excited about, I suppose. Oracle recently, very recently announced Oracle Health Data Intelligence, which is being called an open intelligence ecosystem or innovation.   00;32;31;09 - 00;32;57;21 Talk about what is that and how that helps life sciences. And researchers love to do so. So first of all, the Oracle Health Data Intelligence platform, it's open. It's open to anyone, meaning that anybody could tap into it, regardless of what industry, what part of the health care industry or working life sciences, whichever system, electronic health record system you're you're using.   00;32;58;06 - 00;33;32;24 So it's really flexible from that perspective that anybody can tap into it. And the data is research ready, meaning it's usable, right? We're form forming it, we're standardizing, and we're harmonizing it in a way that you can go and do the research that you need to do and get the insights and generate the evidence that you need. And this will help in such a tremendous way with the challenges that I mentioned earlier, breaking down silos, connecting disparate data sources, being structured and data that's now usable.   00;33;32;24 - 00;33;59;14 Right? That is that is not usable currently and it's in many formats. So customers will be able to or anyone really can tap into usable data sets from thousands of sources. So that's the other thing anyone can participate, contribute data. We're going to pull in data from a number of different places and again, turn that data into information and that information into insights and that insight those insights into evidence.   00;33;59;26 - 00;34;23;25 So and this will include longitudinal health data, real world data. I didn't define real world data, so real world data is basically any data that is not clinical trial data. It's in the real world, right? So you see that the care that's occurring within the physician's office or hospital that's not part of a clinical trial is considered real world data.   00;34;23;25 - 00;34;48;01 So that's longitudinal health data, electronic health records, patient registries, whether it's natural history or safety, product registries, all that is considered real world data. And all of that will be part of the health data intelligence platform. And this is an API driven ecosystem, which means anyone could access it. As I mentioned before, whether you use an Oracle clinical application or not.   00;34;48;27 - 00;35;16;18 And you can rest assured knowing it's running securely and safely on the Oracle Cloud infrastructure and as you know, OCI Oracle cloud infrastructure, not only is it safe and secure, but it's a military grade infrastructure and it's being used by the Department of Defense. So you could trust it is reliable, scalable, and it's getting the job done. And the health data intelligence platform, as you know, we have it, we're building it, improving.   00;35;16;18 - 00;35;36;17 This is really a big part of our future here in Oracle Life Sciences at Oracle and quite frankly, in the broader industry. Well, great. You know, I got my answers. Thanks for being our guest today, Michael. We'll be watching those, watching for those shifting mindsets and the changes coming to life sciences. Certainly, Oracle seems to be leading the way in that area.   00;35;36;28 - 00;35;53;25 If our listeners want to learn more, though, about what Oracle's initiatives are or if they want to get in touch with you, is there a way for them to do that? You know, first, my thanks for having me on. I really enjoyed the conversation and pretty good and a couple tough questions in there. So thank you for that to join it.   00;35;54;04 - 00;36;20;28 Everyone is welcome to go to my page and connect with me. I try to post relevant things on occasion. So Michael from set of enforcing the Oracle dot com and find the Oracle Health Sub page of the Oracle Life Sciences of the Explosive Alexa Science Stage Armageddon Sounds good. That got it. Thanks again, Michael. And to our listeners, we don't want you to miss any episodes of research and action.   00;36;20;28 - 00;36;49;01 So please subscribe to the show. And if you want to learn more about how Oracle can accelerate your own life sciences research, you can just go to Oracle dot com slash life dash sciences and we'll see you next time.

L'invitée : Laura Tatoueix, docteure en histoire moderne Le livre : Défaire son fruit. Une histoire sociale de l'avortement en France à l'époque moderne, Paris, éd. de l'EHESS, 2024. La discussion : Introduction (00:00) Cerner l'avortement et son vocabulaire à l'époque moderne (1:10) L'origine de la recherche, ses dimensions politiques (4:15) Les condamnations religieuses et royales de l'avortement … Continue reading "333. Grossesses et avortements sous l'Ancien régime, avec Laura Tatoueix"

On this episode of Banking on KC, Maria Flynn, founder of Ambiologix, joins host Kelly Scanlon to discuss her journey from engineer to entrepreneur—and now to mentor. Tune in to discover:  Maria's transition from engineer to an influential entrepreneur and how her experience at Cerner paved the way. Insights into her strategic shift towards pharmaceutical applications at Orbis—and the lessons learned from diversifying too soon. How her own experiences as a mentee have shaped her approach to mentoring. Key aspects of her book, “Make Opportunity Happen,” which offers actionable advice and tools for entrepreneurs. Maria's vision for the digital health sector in Kansas City and the role of initiatives like Digital Health KC in fostering startups in this space. Country Club Bank – Member FDIC  

Ce matin, Steven Bellery vous nous emmenez à l'Olympia. Cette scène de légende, installée sur les grands boulevards à Paris, a 130 ans cette année, l'occasion d'une ballade privilégiée en coulisses. Un beau-livre vient de paraître pour célébrer cet anniversaire. Il s'intitule "L'Olympia, scène de légendes", aux Editions du Cherche Midi. Un ouvrage bourré de souvenirs, d'archives, de photos, d'interviews. L'occasion de réaliser à quel point l'Olympia a changé le monde de la nuit parisienne. Premier vrai music hall de France, il a vu les plus grandes stars défiler sur sa scène. Il y a en moyenne 280 événements par an dans la salle. Laurent de Cerner le directeur de l'Olympia nous a ouvert les portes de cet endroit mythique.

Dr. Joseph is the co-author of “Designing for Health: The Human-Centered Approach,” a book that promotes the intentional application of design to the particular needs of clinicians, hospital staff, and patients. We caught up with him in today's Concierge Medicine Today's DocPreneur Leadership Podcast.    Craig Joseph, MD is the Chief Medical Officer of Nordic Consulting Partners, a global healthcare management consulting firm. Craig has 30 years of healthcare and IT experience. In addition to practicing medicine as a primary care pediatrician for eight years, he worked for Epic for six-plus years and has served as chief medical information officer at multiple healthcare organizations.   LISTEN TO FULL EPISODE ON iTUNES ... WATCH OUR INTERVIEW HERE ... Amazon link for the book: https://www.amazon.com/Designing-Health-Human-Centered-Craig-Joseph/dp/0960120505/ref=sr_1_1   While at Epic, Dr. Craig Joseph helped build what is now called the Foundation System. He also assisted in the implementation and optimization of the electronic health record for Epic customers across the United States and Europe.   After leaving Epic, Craig was the CMIO at Agnesian HealthCare, a Cerner/Oracle Health enterprise customer. He has subsequently served as the long-term interim CMIO at Epic-customers Texas Children's Hospital (Houston), El Camino Health (Mountain View, CA), and Seattle Children's Hospital.   Dr. Joseph is the co-author of “Designing for Health: The Human-Centered Approach,” a book that promotes the intentional application of design to the particular needs of clinicians, hospital staff, and patients.   Craig is a Fellow of the American Academy of Pediatrics and the American Medical Informatics Association. He remains actively board-certified in both pediatrics and clinical informatics. Craig Joseph, MD serves as the Chief Medical Officer of Nordic Consulting Partners. He is a board-certified pediatrician and clinical informatician. Craig practiced primary care pediatrics for nine years before moving to Madison, WI to work for Epic. After seven years there, he served as Chief Medical Information Officer for several hospital systems using both Epic and Cerner electronic health records. At Nordic, Dr. Joseph works with hospitals and healthcare systems to help them improve clinician happiness and efficiency. He's recently co-authored a book about applying the principles of human-centered design to healthcare.   Amazon link for the book: https://www.amazon.com/Designing-Health-Human-Centered-Craig-Joseph/dp/0960120505/ref=sr_1_1 Connect with Dr. Jospeh on LinkedIn: https://www.linkedin.com/in/craigjoseph/ Learn more about Nordic Global at our website: https://www.nordicglobal.com/   © Concierge Medicine Today, LLC. ("CMT") All rights reserved.   Disclaimers: All content presented here is for general information purposes only. It is NOT intended to provide medical, legal, professional, accounting or financial advice. No warranties or guarantees are assumed or implied and user(s) releases Concierge Medicine Today, LLC, its agents, representatives, affiliated brands/companies and/or guests from all damages, liability and/or claims. Be advised, some references, companies, individuals, products, services, resources and/or links may be out-of-date. Concierge Medicine Today, LLC does not update content past its release date. User(s) assume all risk and liability with any use of the content as well as third party links. Concierge Medicine Today, LLC., has no formal peer review and, therefore, cannot guarantee the validity of information and/or content contained on its web sites, podcasts, and/or all content it produces or releases. While some of our speakers may be licensed Physicians, they are not your Physician. Please consult your Physician related to anything you may have read or heard or have questions about or call 911. The views, thoughts, and opinions expressed are the speaker's own and do not necessarily represent the views, thoughts, and/or opinions of Concierge Medicine Today, LLC. The "Concierge Medicine Today, LLC" ("CMT") name and all forms and abbreviations are the property of its owner and its use does not imply endorsement of or opposition to any specific organization, product, or service. Additional disclaimers, releases, terms of use and conditions apply also to the production and/or use of this content, https://conciergemedicinetoday.org/tcpp/.

Chandler Malone is a startup founder and entrepreneur in the technology space. He has a background in venture capital and has worked at various firms, including iSelect Fund and Atento Capital. Chandler co-founded the software company Boot Up, which focuses on workforce development and upskilling retail workers for technical roles. He recently launched a new company called Path AI with his partner Chris Gray, which aims to provide AI-powered career mentorship and job search tools. In this episode, we interview Chandler Malone, a startup founder and entrepreneur in the technology space. Chandler shares his background and journey, from his early entrepreneurial experiences in college to his work in venture capital and the launch of his own companies. He discusses his latest venture, Path AI, which focuses on providing AI-powered career mentorship and job search tools. Chandler also shares insights and tips for founders, including fundraising strategies and the importance of metrics and communication skills. If your company is looking to scale its AI initiatives, head over to Tesoro AI (www.tesoroai.com). We are experts in AI strategy, staff augmentation, and AI product development. Founder Bio: Chandler has been focused on helping people reach their economic potential throughout his entire career via his work at Bootup and The Family. In Chandler's 3 years as the CEO of Bootup, the company helped thousands of people get their first jobs in tech for over $200M in annualized salaries at companies like JP Morgan Chase, Home Depot, Mailchimp, Cerner, and more. Chandler is also founder of The Family, a venture studio focused on Black and Brown founders. Over the past 4 years, The Family has invested in 10 Black and Brown founders with an estimated market cap of over $300M. Time Stamps: 02:43 Introduction and background of Chandler Malone 06:23 Challenges of startup fundraising 08:49 Transition from working at Tinto Capital and Launching Boot Up 11:29 Introduction to Path AI and the need for AI tools in the hiring process 15:37 Advantage of AI advisors for specific industries 18:44 Advantages of sourcing talent from South America 23:22 Incorporation of AI into the product using OpenAI, Anthropic, and Llama2 25:24 Importance of delivering value and creating awareness for customers 26:46 Looking for people who care about helping others and economic mobility 29:30 Funding journey: self-funded, upcoming funding round 32:53 Finding investors with expertise in the relevant industry 33:55 Selecting the most compelling and honest metrics for investors 35:15 Communication with partners, associates, and analysts in the funding process 38:13 How to get in contact with Path AI team and whats coming new in 2024 Resources Company website: https://yourpath.ai/ LinkedIn: https://www.linkedin.com/company/yourpathai/ Instagram: https://www.instagram.com/yourpath.ai/ Other: https://www.thefamily.studio/

durée : 00:36:25 - Le 18/20 · Le téléphone sonne - 15 millions de spectateurs, 10 500 athlètes mais combien de travailleurs pour les Jeux Olympiques de 2024 ? Chantiers, emplois, sécurité, précarité... Arrêtons-nous ce soir sur l'aspect social des JO, pensé pour la première fois dans une charte sociale

Travel RN Coach (@lindseys_leisures), Lindsey, joins Nurses Uncorked to discuss her recent viral video in which a patient made alarming threats against their former ER nurse at Peace Health Southwest Medical Center. The repeated threats included very specific identifying details of the nurse's family, begging the question, how were they able to find this information?   The answer lies in The 21st Century Cures Act, first passed in 2016. Many medical professionals remain unaware of The Cures Act. And patients often do not understand the complications it poses to their care. Why do patients have access to nurses' full names? Is this a safety risk that employers should mitigate? What role do electronic health records, like Epic, Cerner, or Meditech play? Should patients have real-time access to their medical records? Join us as we break down The Cures Act and it's ramifications.    References: https://www.congress.gov/114/bills/hr34/BILLS-114hr34enr.pdf National Public Radio (NPR): Winners and losers with the 21st Century Cures bill. http://www.npr.org/sections/health-shots/2016/12/02/504139105/winners-and-losers-if-21st-century-cures-bill-becomes-law.    Follow Lindsey: https://www.tiktok.com/@lindseys_leisures?_t=8k1XIaaTQr9&_r=1 https://www.instagram.com/lindseys_leisures?igsh=MTd5Z2tleHdwYXJsbg== https://lindseysleisures.net/ https://youtube.com/@lindseys_leisures?si=LiWRkky8bgNVbera   New episodes of Nurses Uncorked every Tuesday. Help us grow by giving our episodes a download, follow, like the episodes and a 5 ⭐️ star rating! Please follow Nurses Uncorked at!  https://www.tiktok.com/@nurses.uncorked?_t=8drcDCUWGcN&_r=1 https://instagram.com/nursesuncorked?igshid=OGQ5ZDc2ODk2ZA== https://youtube.com/@NursesUncorkedL https://www.facebook.com/profile.php?id=100094678265742&mibextid=LQQJ4d You can listen to our podcast at: https://feed.podbean.com/thenurseericarn/feed. https://podcasts.apple.com/us/podcast/nurses-uncorked/id1698205714 https://spotify.link/8hkSKlKUaDb https://nursesuncorked.com     DISCLAIMER: This Podcast and all related content [published or distributed by or on behalf of Nurse Erica, Nurse Jessica Sites or Nurses Uncorked Podcast is for informational purposes only and may include information that is general in nature and that is not specific to you. Any information or opinions expressed or contained herein are not intended to serve as or replace medical advice, nor to diagnose, prescribe or treat any disease, condition, illness or injury, and you should consult the health care professional of your choice regarding all matters concerning your health, including before beginning any exercise, weight loss, or health care program.  If you have, or suspect you may have, a health-care emergency, please contact a qualified health care professional for treatment.   Any information or opinions provided by guest experts or hosts featured within website or on Nurses Uncorked Podcast are their own; not those of Nurse Jessica Sites, Nurse Erica or Nurses Uncorked Company.  Accordingly, Nurse Erica, Nurse Jessica Sites and the Company cannot be responsible for any results or consequences or actions you may take based on such information or opinions.

Sersie and Gigi sit down with the amazing vegan superhero, Dr. Daphne Bascom. Dr. Bascom shares her journey to lifestyle medicine and becoming vegan. They have a candid conversation about Health Equity and how lifestyle medicine concepts can help underserved communities prevent, treat, and possibly reverse common chronic diseases. About Daphne Bascom: Daphne Bascom, MD, PhD, is a certified health coach and Coaching Team leader with The Vegan Gym.  Before relocating to Virginia to join the MITR corporation, Daphne was the Vice President of Population Health for St. Luke's Health System in Kansas City. As part of the population health team, she partnered with health systems, payors, and community partners to support managed care contracts with multi-million-dollar performance-based incentive opportunities. Daphne continues to work as a consultant for MITRE Corporation as a Principal Health Practice and Systems Engineer with the VA Health, Innovation & Central Office. As part of her multifaceted career, Dr. Bascom was a senior vice president and the medical director at the YMCA of Greater Kansas City. In 2018, Dr. Bascom also served as Y-USA's Chief Health Officer. In this role, she helped local Ys define and operationalize local clinical integration strategies while leveraging existing evidence-based health programs.    Dr. Bascom was previously a Vice President and Chief Medical Officer with Cerner Corporation. Before re-joining Cerner, Dr. Bascom was Chief Clinical Systems Officer for Cleveland, Ohio's Cleveland Clinic Health System. During her time at the clinic, Dr. Bascom was part of the innovative team implementing the enterprise health record. Daphne also partnered with the Wellness Institute to support the Lifestyle 180 program. Dr. Bascom completed her fellowship in microvascular and reconstructive surgery of the head and neck at Oregon Health Sciences University and her medical degree, internship and residency in otolaryngology-head and neck surgery at the University of Pittsburgh Medical Center. She earned her PhD in physiological sciences at the University of Oxford, Laboratory of Physiology, in the United Kingdom. The Vegan Gym: https://thevegangym.com/ Daphne's Websites Wingman Wellness: www.WingmanWellness.com Perfectly Planted: www.PerfectlyPlanted22.com Social Media Instagram: @WingmanDaphne Facebook: https://www.facebook.com/dabascom Twitter: @DaphneBascom YouTube Wingman Wellness: https://www.youtube.com/@dabascom Perfectly Planted: https://www.youtube.com/@perfectlyplnted6071 LinkedIn: https://www.linkedin.com/in/daphne-bascom/ Healthy Christian Woman Bootcamp: https://www.healthyformypurpose.com/healthy-christian-woman-bootcamp --- Send in a voice message: https://podcasters.spotify.com/pod/show/healthyformypurpose/message

Technology. I'm of a mixed mind. Broadly, I think technology is a blessing for humanity. It saves lives. In my small corner of the world I interview guests from across the nation over Zoom, and deliver the final product via the magic of podcast. That may or may not be a blessing depending on your opinion of Off the Record. But it goes to show you its reach and impact. But it also strikes me as naive to paint technology as a universal good. Does anyone think smartphones and social media wars have unambiguously improved the country, or how we communicate as a species? How about ransomware and AI hallucinations? One thing that is true: Love it or hate it, technology is here to stay. And is increasingly ubiquitous, ever more powerful, and something we cannot work without. I wanted to talk to someone whose organization is a heavy tech user. Not a vendor representative, but a customer. To get a more objective look at some of the tech we're using in CDI and coding. Joining me for this episode is Kory Anderson, Medical Director of Physician Advisor Services, CDI, & Quality, and Enterprise Medical Staff President at Salt Lake City, Utah based Intermountain Health. It's an organization I consider very tech forward. On this show we cover: His role at Intermountain, a “day in the life” of Kory Anderson Intermountain's CDI/coding tech stack, with a focus on computer assisted physician documentation (CAPD). Impact on MD practice and CDI metrics and out of the box use cases. How smart is current tech? Does it weaken critical thinking, or will it replace CDI and coding professionals?  The drawbacks/limitations that vendors don't tell you about. What can't it do, and where it still falls short. Intermountain's ongoing merger with SCL Health, a big obstacle of which includes a migration from Cerner to EPIC A cool new addition to the OTR Spotify playlist

In this episode we are joined by Amy Andersen, Vice President, Market Development Enterprise & Cloud Venture at Oracle to discuss Oracle recent acquisition of Cerner, their Modern Data Platform, fraud detection, and more!This episode is sponsored by Oracle.

Welcome to Episode 175 of Autism Parenting Secrets. This week, we focus on how you can upgrade the way you manage, organize, and use your child's health data.  Our guest is Dave Korsunsky, CEO and Founder of Heads Up.Dave recognized an opportunity to build a software solution that makes it easier for anyone to take control of their health through better use of their data.It's impossible to feel good about the decisions you're making for your child if you feel unclear, lost, or confused about what's happening right now.Understanding your child's health biomarkers is important.And paying for labwork and other testing, while expensive, can be very useful.But not doing anything with the data you have is a waste of time, energy, and money. The secret this week is…Better DATA = Better DECISIONSYou'll Discover:How To Reduce The Overwhelm (4:43)The Power of the TREND LINE (8:58)Why Centralization Is Essential (13:32)How Tracking Helps Improve Sleep (18:18)Arguably THE Top Biomarker To Measure (25:08)How To Leverage Wearables Safely (29:37)The Habit That's Disasterous For Sleep (31:17)How You Can Make PDFs Come To Life (33:17)About Our GuestCEO and Founder of Heads Up. Dave has fifteen years of experience working for industry-leading technology firms and most recently served as Director of Technical Alliances at VMware (NYSE: VMW), Inc., where he led strategic partnerships with global EHR companies, including EPIC, Cerner, McKesson, GE, Allscripts and many more. Dave went on to lead sales engineering at CloudPhysics, a big data firm collecting and analyzing over 80B data points per day. As an avid health enthusiast, he recognized an opportunity to build a software solution that makes it easier for anyone to take control of their health through better use of their data.Heads Up HealthReferences in The Episode:For 30 Day Free Trial, go to Heads Up HealthBreathe: The Science Of A Lost Art by James NestorAdditional Resources:Take The Quiz: What's YOUR Top Autism Parenting Blindspot?To learn more about Cass & Len, visit us at www.autismparentingsecrets.comBe sure to follow Cass & Len on InstagramIf you enjoyed this episode, share it with your friends.

Dr. David Feinberg was CEO of Geisinger and UCLA Health, then led Google Health before becoming CEO of Cerner. For the past year he's been Chairman of Oracle Health. So, it's safe to say he knows a thing or two about healthcare IT!Dr. Feinberg joins  the show to discuss interoperability, AI, health equity, and much more!

Aaron Sin, MD, is passionate about advancing child health and believes that pediatricians deserve cutting-edge software mirroring the excellence and importance of their work. He is currently the co-founder and CEO of Develo, a company dedicated to building end-to-end software extending beyond the traditional EMR for independent pediatric practices.Aaron previously served as a product leader at Innovaccer, launching value-based care products for accountable care organizations, health systems, and payers, and has also been a consultant at McKinsey, leading projects across the healthcare value chain. He is a published pediatrics academic researcher with experience with a large-scale Cerner to Epic implementation in both outpatient and inpatient settings. Aaron holds an MD from Stanford University and a BS in Biomedical Engineering from Yale University. Aaron resides in San Francisco with his wife, Angela, and their newborn son.This episode is made possible by a generous sponsorship from Develo— go to getdevelo.com to learn more. https://aapexperience23.eventscribe.net/preview.asp?boothTarget=677920https://www.linkedin.com/company/getdevelo/ https://podcasts.apple.com/us/podcast/the-pediatric-lounge/id1622652206?i=1000629184792https://podcasts.apple.com/us/podcast/the-pediatric-lounge/id1622652206?i=1000623042252Support the show

Chandler Malone has been focused on helping people reach their economic potential throughout his entire career via his work at Bootup and The Family. In Chandler's 3 years as the CEO of Bootup, the company helped thousands of people get their first jobs in tech for over $200M in annualized salaries at companies like JP Morgan Chase, Home Depot, Mailchimp, Cerner, and more. Chandler is also the founder of The Family, a venture studio focused on Black and Brown founders. Over the past 4 years, The Family has invested in 10 Black and Brown founders with an estimated market cap of over $300M. --- Support this podcast: https://podcasters.spotify.com/pod/show/tavamultimediagroup/support

In this spontaneous podcast review on the final afternoon of Oracle CloudWorld 2023, Jon Reed and Brian Sommer compare what they learned, culminating in Sommer's quip, "You may have to partner with your enemy, because that's what your customer wants." Customers definitely want more vendor options in their strategic mix - did CloudWorld support that premise? Is Oracle's generative AI messaging differentiated? Does Oracle have an industry applications advantage from their acquisitions, which go well beyond Cerner? And: did Larry Ellison's strong keynote push on healthcare resonate? These are some of the topics we hash out during this 25 minute recap. Production note: Jon's audio was a bit quiet due to a tech glitch, worked on tweaking that as best possible in post production, hopefully it will be solid enough for this time around.

Walmart is reportedly considering buying a majority stake in ChenMed. Two major hospital systems are switching their EHRs from Cerner to Epic. And, two Wisconsin health systems take another step towards a merger. That's coming up on today's episode of Gist Healthcare Daily. Hosted on Acast. See acast.com/privacy for more information.

   I waited 6 years for www.turnpiketroubadours.com to release a new album this morning and was so excited to hear it.  Then I read www.tonyskansascity.com and it took the prize for best package under the tree.  Yes, real journalism is back!  Tony reports that the Clay County poll against the Royals relocating to NKC is completely and utterly fake and he found out who paid for it. This is great, great work and shines light on disgusting, behind the scenes dirty dealing.    Trump's mugshot may become the most famous photo of this century in American history but how he decided to deal with it was classic Trump.  In doing it his way, nobody is talking about the charges he faces, he's got everyone talking about silly stuff, which proves the whole thing is silly.    T-Mobile is cutting 5000 jobs and that's bad for KC.  Remember how great Sprint and Cerner were for KC before Bidenomics?    The Chiefs believe they have 8 NFL wide receivers in camp but will only keep 6 or 7.  I make a case for keeping 7.    Shannon Sharpe has a new tv gig starting next week, Joe Biden wants to take away you ceiling fan and keep you to two alcoholic drinks per week and what do you know... paper straws are worse for the environment than plastic.    

In today's episode of Tech Talks Daily, we are privileged to host Shival Seth, the dynamic Chief Technology Officer at Grand River and St. Mary's Hospital in southwestern Ontario, Canada. Serving over a million patients, Shival's mantra is "What you lack in skills you make up in will," which has proved integral to his leadership role in this diverse community. Our conversation unfolds as Shival explains the journey of business transformation, specifically focusing on the use of technology to enhance services for administrators, clinicians, and patients alike. With an array of innovations in staff scheduling, HR processes, and patient scheduling, we gain an insight into the challenges and solutions found in healthcare technology. Shival will walk us through his collaboration with HIMSS and the Cisco Customer Experience (CX) Team to conduct an INFRAM (Infrastructure Adoption Model) assessment. This helped map out their technology infrastructure capabilities and align them with clinical, strategic goals and international standards. Shival's insightful explanation on how the INFRAM assessment led to significant investments in technology infrastructure will be a valuable lesson for all tech leaders. A major part of our discussion will delve into how Cisco's Webex has revolutionized the hospital's operations, allowing for secure, virtual care. From emergency consultations to upgrading meeting rooms, Shival demonstrates the power of technology in modern healthcare. We'll also cover the role of Cisco security and Full Stack Observability in safeguarding the hospital's network, and Shival's future vision for pioneering virtual triaging and abolishing traditional waiting rooms. Key discussion topics include: • The role of Webex Connect in virtual care and hybrid work • Webex's integration with Cerner and its inclusivity tools • The efficiency of Webex Connect (CPaaS) in staffing, patient monitoring, and scheduling • The value of a unified view in security tools like Duo, Umbrella, ISE, and ThousandEyes • How Cisco Full Stack Observability enables proactive problem-solving • The importance and value of an INFRAM assessment Join us as we venture into the exciting world of healthcare technology with Shival Seth, a pioneer making waves in his industry.